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Two standard tests for infectious mononucleosis (the 
Davidsohn differential and the ox cell hemolysin test) and 
ten sl ide tests Monotest (Wampole), Monospot (Ortho), 
Monosticon (Organon), Diag1uto I. M. (Beckman), I. M. Kit 
(Micro. Res. Corp.), Mono-Diff (Wampole), Bacto-Hetro1 
(Difco), Monosticon Dri-Dot (Organon), Monophi1e (BDS) and 
Rythrotex (BMC) were evaluated as they were used in 50 
laboratories within the state of Utah plus two referee 
laboratories outside the state. The state proficiency 
testing program for infectious mononucleosis was modified 
so that the desired evaluation survey data could be 
obtained. The sensitivity, specificity, reproducibi1 ity 
(within and between shipment) and percent agreement with 
target results were determined for each test. 
Factors which might have affected the test results were 
evaluated to determine which were correlated with good per-
formance. These factors included: formal education of the 
technologist performing the test, professional affi1 iation 
of the technologist, technologist's experience, technolo-
gist's area of major interest, type of laboratory, size of 
laboratory, number of tests performed, use of the test 
(screen, confirm or both), technologist's experience with 
the test and procedural differences. 
Since there is a critical need for evaluation survey 
data in a1most every area of cl inical laboratory testing 
and since there are in existence numerous proficiency 
testing programs in these areas, it is felt that an 
enormous amount of valuable information could be relatively 
easily obtained by similar modifications of existing 
proficiency testing programs. 
xiii 
INTRODUCTION 
The primary purpose of proficiency testing is to allow 
an outside agency to estimate the level of competence that 
could be expected from a participating laboratory and 
thereby aid in making decisions concerning the accept-
abil ity of the service provided to patients. This objec-
tive is obtained by periodic shipment of specimens to be 
identified or tested for the presence of certain 
constituents. 
The primary purpose of evaluation surveys on the 
other hand is to obtain statistical data concerning the 
sensitivity, specificity and reproducibil ity of the various 
test procedures being employed. This has been done in the 
past, e.g., in the syphil is serology evaluation survey con-
ducted by CDC in 1956 (108), by obtaining large numbers of 
positive and negative specimens and shipping them to a 
large number of laboratories to be examined. In spite of 
the critical need for this type of information, evaluation 
surveys have not been made because of the immense logistical 
and financial problems involved. 
In order to fill the void in the area of evaluation 
surveying and at the same time circumvent the major problems 
that have created this void, the hypothesis was suggested 
that evaluation survey data can be derived from existing 
proficiency testing programs with only minor modifications. 
Volumes of proficiency testing data are generated each year 
which are of 1 ittle value in determining the rel iabil ity of 
the tests being employed because variations in the proce-
dures are not identified and the results do not al low 
statistically significant statements to be made. 
A review of the 1 iterature reveals that there have 
been no evaluation surveys made to determine the specifi-
city, sensitivity and reproducibil ity of the numerous 
tests and kits used to test for infectious mononucleosis. 
In fact, in the whole field of serology there is only one 
area in which critical evaluation surveys have been per-
formed, that is, in syphil is serology; the last such 
evaluation was carried out in 1956 (47). 
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Evaluative data are obtained from research laboratories 
almost exclusively. Comparative results are reported on 
tests performed in only one laboratory and that is often 
the laboratory of the author of the test. Much raw data is 
available in the form of proficiency testing results but 
such data are inadequate because proficiency testing is de-
signed to determine laboratory performance, not test 
performance. 
An example taken from a prel iminary examination of 
Utah state proficiency testing results for infectious 
mononucleosis shows some of the possible results and pro-
blems (Table I). Appl ication of the chi square (X 2) test 
to the Monotest (Wampole) results indicates that this test 
TABLE I 
Preliminary Evaluation of Tests for Infectious Mononucleosis 
from Utah State Proficiency Testing Data 
Sensitivity Specificity Reproducibil ity 
# % # % # % 
Ox-Cell Hemolysin 9/9 100 6/6 100 5/5 100 
Pau l-Bunne 11 3/3 100 2/2 100 2/2 100 
Monotest (Wampole) 9/12 75 8/8 100 8/8 100 
I.M. Kit (Micro.Rsh.Corp.) 6/6 100 4/4 100 4/4 100 
Monosticon Dri-Dot (Organon) 3/3 100 2/2 100 2/2 100 
Monospot (Ortho) 3/3 100 2/2 100 2/2 100 
Improved Monotest (Wampole) 3/3 100 2/2 100 2/2 100 
Monosticon (Organon) 3/3 100 2/2 100 2/2 100 
Total 39/42 92.8 28/28 100 27/27 10Q 
# = # correct/#done 
Sensitivity = % of positive samples positive 
Specificity = % of negative samples negative 
Reproducibil ity = % of matched samples with identical results 
w 
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was significantly less sensitive than the other tests 
(.OI<P<.OS). Differences probably exist between all the 
tests for the other parameters as well, but the small sample 
size and poor experimental design do not allow their 
detection. 
We hoped to correct these deficiencies by modifying 
the proficiency testing program of the Utah State Division 
of Health so that reI iable data could be obtained to 
evaluate the sensitivity, specificity and reproducibil ity of 
the tests for infectious mononucleosis used by the 
laboratories in Utah. 
The significance of this work is that it wil 1 allow 
tests to be evaluated without the enormous expenditure of 
time and material that has been involved in the past. Be-
cause of the cost deterrent most of the tests currently 
being employed in cl inical and publ ic health laboratories 
have not been investigated to determine their rel iabil ity. 
The original contribution made by this research is that it 
permits the use of existing programs to provide badly needed 
information about tests which have not been obtainable by 
other methods. 
Although this research was 1 imited to tests for in-
fectious mononucleosis in Utah, it is anticipated that 
similar investigations could be conducted on other serologic 
tests and by other organizations. The adoption of similar 
procedures by agencies involved in proficiency testing would 
result in a wealth of valuable information that is not now 
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available and would correct the present deplorable condition 
of using unevaluated or underevaluated tests. Cl inicians 
and laboratory personnel would then have reliable informa-
tion on which to base their judgments concerning the use of 
laboratory tests. 
Evaluation surveys such as this could be used to 
develop standards for reagents, techniques, and performance 
I ike those established for syphil is serology. The benefits 
of standardization are demonstrated by proficiency testing 
results. The mean score (percentage of referee laboratory 
values) for laboratories participating in Utah State's 
syphilis serology proficiency testing is 98.2 ~4.9 whereas 
the mean score for immunology (non-syphil is serology) is 
89.0 + 17.7. This difference is highly significant 
(P<.OOl) suggestions that with proper evaluation and 
standardization of non-syphil is serologic tests could 
markedly improve test performance. 
Since the tests in these two areas involve similar 
procedures, most of the difference must be due to the fact 
that tests for syphil is have been thoroughly investigated 
and standardized. The development of such standards for 
tests on the area of immunology will require an ongoing 
effort to evaluate new tests, new reagents and new 
laboratories. 
REVIEW OF LITERATURE 
Infectious mononucleosis or glandular fever was first 
described cl inica1ly by Pfeiffer in 1889 (81). However, 
Hoagland (50, 53, 54) does not bel ieve that the disease 
Pfeiffer described was infectious mononucleosis because of 
its cl inica1 characteristics and he objects to classifying 
a disease as a mononucleosis when blood studies were not 
done. The first case of the disease in the United States 
was reported to have been observed by West (119) in 1896. 
The original description of the disease characterized 
it as a febrile illness accompanied by sore throat and 
general ized enlargement of lymph nodes. TUrk (107) in 1907 
was the first to associate abnormal blood cells with the 
disease and to categorize the disease as a form of acute 
lymphatic leukemia. 
In 1920 Sprunt and Evans (96) introduced the name in-
fectious mononucleosis and described the unusual cells 
encountered. In 1923 Downey (35) described the morphologi-
cal changes in these cells in minute detail. 
In 1911 Forssman (43) discovered the immunization of 
rabbits with sheep erythrocytes caused the production of an 
antibody which was toxic to guinea pigs and that guinea pig 
kidney contained an antigen which reacted with this rabbit 
antibody. He also found that the blood and organs from pigs, 
cows, rats, and rabbits contained no antigen of this type 
which came to be called Forssman antigen. Further studies 
(2) into the nature of the Forssman antibody revealed that 
it was but one of a family of heterophile antibodies which 
have been characterized by Davidsohn and Walker (24) as 
lIan tibodies that have the abil ity to react with antigens 
that are apparently entirely unrelated to those which sti-
mulated their production. II Forssman antigens are widely 
distributed in nature including group A and B agglutinogens 
in human blood; in horses, camels, sheep, mice, dogs, cats 
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and chickens; in the Gram negative bacill i of the salmonellae 
and col iform group; in pneumococci; in toxoplasma and other 
parasitic organisms; in some fungi; and a variety of 
hemagg1utinogens occuring in viral diseases (110). 
Davidsohn in 1929 (22) estab1 ished the casual relation-
ship between injected horse serum and the elevated agglutinin 
and hemolysin titers for sheep erythrocytes and appl ied it 
to the serological diagnosis of serum sickness. Later he 
(23) showed that normal control subjects possessed anti-
sheep agglutinins of a heterophile nature. 
Two years later Paul and Bunnell (80) made a heterophile 
ant i body su rvey of diseases tha t they cons i dered to be re-
lated to serum sickness. They discovered "quite by accident ll 
that heterophile antibodies were elevated in infectious 
mononucleosis. This test is entirely nonspecific and is 
therefore a presumptive test for infectious mononucleosis. 
I n 1 93 5 Stu art (1 0 1 ), B ail e y and Ra f f e 1 ( 2), and 
Davidsohn and Walker (24) independently differentiated the 
antibodies for Forssman antigen and those of serum sickness 
from infectious mononucleosis by the absorption patterns of 
sheep agglutinins. In 1941 Barrett (3) described the tech-
nique of absorption and titration which is now widely used. 
This differential test has proved to be accurate and 
specific, although time consuming. 
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Beer (6) in 1936 reported antibodies in infectious 
mononucleosis serum for erythrocytes of sheep, beef, goats, 
horses, pigs, guinea pigs, rabbits and dogs. He found 
elevated hemolysin titers for beef red blood cells and 
increased agglutinin titers for sheep, goat and horse cells. 
The titers for horse erythrocytes were the highest. 
Butt and Foord (12) in 1935 developed the first rapid 
test when they reported that if sera which showed a posi-
tive Paul-Bunnell titer (80) were mixed with sheep cells in 
a hanging drop preparation, agglutination was immediate. 
Following this observation, Straus (99) developed rapid sl ide 
and tube tests. Similar sl ide screening tests have been used 
with considerable success by others (77, 85, 112), the 
numbers of false results being small or absent. The advan-
tage offered by these tests is that they el iminate the need 
of performing the more laborious tests on a majority of sera. 
Gleeson-White et. al. (45) reported that infectious 
mononucleosis sera agglutinated trypsinized beef erythrocytes 
in higher dilutions than normal sera. This was confirmed by 
Tomcsik and Baumann (106). 
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Wgllner (123) in 1955 developed a differential test for 
infectious mononucleosis which took advantage of the fact 
that serum from patients with infectious mononucleosis 
agglutinates papain treated sheep cells in lower dilutions 
than untreated sheep cells. Non-infectious mononucleosis 
serum showed the opposite reaction. The diagnostic value 
of his test has been confirmed (30, 78, 94). 
In 1968 Henle, Henle and Diehl (49) reported the 
association of antibodies to a herpes-type virus (Epstein-
Barr (EB) virus) and infectious mononucleosis. Although 
the EB virus is suspected of being the etiological agent 
of infectious mononucleosis this relationship has not yet 
been conclusively proven. Indirect fluorescent antibody 
tests using the EB virus antibodies have been developed, 
but they are not practical from a cl inical standpoint be-
cause of uncertain specificity of the antibodies and because 
once a patient develops antibodies, titers remain elevated 
for years. 
Because of the inconvenience of performing the stan-
dard tests, a number of rapid sl ide agglutination tests 
have been developed over the years (23, 56, 71, 77). The 
first was developed by Tannen (104) in 1953. These slide 
tests employ a variety of reagents and techniques and con-
sequently have varying specificities and sensitivities. 
In spite of the existence of a number of specific 
serological tests, a number of authors have emphasized that 
a complete diagnostic study of a patient suspected of having 
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infectious mononucleosis should still include cl in;cal mani-
festations and morphological examination of the blood as well 
ass e r 0 log i ca 1 t est s (5 3) • 
I. SHEEP CELL HETEROPHILE SCREENING TEST (Moloney and 
Malzone (77) 
The sheep cell screening test is a test used in many 
laboratories as a preliminary test of patient sera to iden-
tify those which will require further testing in order to 
determine if the patient has infectious mononucleosis. 
Moloney and Mal zone (77) describe a typical sheep cell 
sl ide screening test for infectious mononucleosis. Accord-
ing to their procedure, fresh sheep cells were washed 
three times with a minimum of 10 volumes of normal saline, 
centrifuged, and the packed cells are stored at 4 C. One 
drop of the test serum is added to one drop of a freshly 
prepared 10% suspension of the sheep cells on a glass sl ide 
and thoroughly mixed. Any macroscopic agglutination appear-
ing within one minute is accepted as presumptive evidence 
of infectious mononucleosis and the serum is then tested by 
a more specific technique. 
This test is quite sensitive but it is not very 
specific. Davidsohn (32) reported a 7.6% incidence of false 
positive reactions with it. 
J J. PRES UMPT I VE HETEROPH J LE TES T (Pa u 1 and Bunne 11 (80 )) 
Paul and Bunnell (80) first applied the heterophile 
test to infectious mononucleosis in 1932. This test and 
modifications of it have also been publ ished by other 
investigators (3, 55, 60). 
The test consists of heat inactivating the test serum 
for 30 min at 56 C, then preparing a 1:5 and subsequent two 
fold dilutions. To 0.25 ml of each serum dilution is added 
0.1 ml of 2% sheep erythrocytes which are then mixed and 
incubated at room temperature for two hours. The tubes are 
then read for agglutination and the titer reported. 
1 1 
During the active stage of illness, a sheep agglutinin 
titer of 224 or higher favors the diagnosis of infectious 
mononucleosis (30). However, the titer of heterophile anti-
body has not been found to correlate with severity or 
duration of the disease or with incidence of comp1 ications 
(5). 
This test is simple and sensitive but lacks specificity 
(30, 90). False positive tests have been reported in 
Hodgkin's disease, sarcoma, polycythemia, agranulocytosis, 
leukemia and tuberculosis (46, 90). Bunnell (11) maintained 
that high titers (99) were diagnostic for serum sickness 
or infectious mononucleosis. 
In small laboratories the requirement for maintaining 
a supply of fresh sheep cells can be inconvenient and 
expensive. 
The original procedure called for overnight refrigera-
tion before reading the titer but later authors have 
recommended incubation at room temperature (25, 94). Hall 
(47) has reported that in spite of variations in incubation, 
1 2 
centrifugation, endpoint reaction and other parameters there 
was no apparent correlation between modifications of the 
procedure and the results obtained. 
II I. DIFFERENTIAL ABSORPTION TEST (Davidsohn and Walker (24)) 
Davidsohn (24, 25, 26) at the same time as others (2, 
101), discovered that patients with serum sickness and 
infectious mononucleosis could be separated from each other 
and from patients with other heterophile antibodies by 
differential absorption of their sera with suspensions of 
guinea pig kidney and boiled beef erythrocytes. 
To perform this test, a sample of serum is absorbed 
with guinea pig kidney and another sample with boiled beef 
erythrocytes. The titer of agglutinins for sheep erythro-
cytes is determined for each serum after absorption (30). 
As defined by Davidsohn et a1. (27) the differential test 
for infectious mononucleosis is positive if the titer of 
sheep agglutinins after absorption with guinea pig kidney 
is not more than three tubes lower than the titer of the 
presumptive test and the sheep agglutinin titer is at least 
four tubes lower after absorption with beef erythrocytes (72). 
Absorption Patterns for Various Heterophile Antibodies (9) 
Type of 
Heterophile Antibody 
For s s rna n (" nat i veil ) 
Serum Sickness 
Absorbed by 
Guinea Pig Kidney 
Yes 
Yes 
Infectious Mononucleosis No or Sl ight 
Absorbed by 
Beef Erythrocytes 




A number of investigators (5, 13, 14, 32, 72) have 
reported using only absorption with guinea pig kidney. They 
have also reported various criteria for determining positive 
tests which could be ambiguous when compared with the 
Davidsohn interpretation. Ha11 (47) has pointed out that 
the interpretation of the results of a positive heterophile 
test is based on the differential absorption pattern which 
requires the use of both guinea pig (or horse) kidney and 
beef cell antigens. Beef cell absorption is necessary to 
distinguish sheep ce11 antibodies which are not related to 
infectious mononucleosis. Bender (8) reported a case of 
Hodgkin's disease which would have been misdiagnosed if 
beef cell absorptions had not been performed. 
The sheep agglutinin differential absorption test is 
by far the most thoroughly investigated reference test 
available at the present time (31). On the basis of 600 
carefully studied cases, Bender (8) concluded that there 
is no satisfactory evidence that a positive differential 
test for infectious mononucleosis can be dupl icated by 
any other condition. In cases with sheep agglutinin titers 
of 28 or below in the presumptive test, the use of horse 
cells is recommended (31). 
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IV. OX CELL HEMOLYSIN TEST (Mason (74)) 
Elevated beef hemolysin titers in sera of patients with 
infectious mononucleosis were reported by Bailey and Raffel 
(2) in 1935, but were not used in a cl inical test until 
1951. Mason (74) app 1 i ed the ox cell hemol ys i n .test to the 
diagnosis of infectious mononucleosis and reported that it 
was more specific than the classical heterophile antibody 
tests (6, 25, 80). Since then, many investigators have 
confirmed the value of this reaction in the serological 
diagnosis of infectious mononucleosis (30, 37, 69, 76, 82). 
Peak beef hemolysin titers were found in sera from patients 
within 2-3 weeks after the onset of illness (30). All sera 
tested within 6 weeks after onset of illness were still 
positive. Mason (74) and Ley ton (69) also observed that the 
ox cell hemolysin appeared earl ier and remained elevated 
longer than the sheep cell aggl uti ni ns. Lee, et. al., (62) 
bel ieve that sheep erythrocyte ag~lutinins and ox cell 
hemolysins are physically inseparable and imply that tests 
using these antibodies should have equal re1 iabil ity. 
The procedure used by Cabrera and Carlson (14) and 
Mikkelsen (76) is as fol lows: To each of 10 tubes is added 
0.5 m1 of an 0.85% sal ine solution containing 0.1 gm of 
ma 9 n e s i u m s ul p ha t e per 1 i t e r • Tot he firs t tub e , o. 5 m 1 of 
inactivated serum is added, and serial dilutions are made. 
To each tube 0.5 m1 of a 1 :15 dilution of complement and 0.5 
m1 of a 2% suspension of washed beef erythrocytes are added. 
Tubes are shaken and incubated in a 37 C waterbath for 15 
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minutes. The tubes are then centrifuged at 2000 rev/min for 
two minutes and compared with a 50% hemolysin standard, which 
is prepared by adding 0.5 ml of a 2% suspension of beef 
erythrocytes to 2 ml of distilled water. The titer is the 
reciprocal of the dilution of the tube which compares most 
closely to the standard. Titers of 48 or less are considered 
negative; 96 to 384, suspicious; and 768 or higher, positive. 
Hall (47) reports that there are two more commonly used 
ox cell hemolysin techniques, the CDC method and the Peterson 
method. The main differences are in the serum diluent, 
incubation time and significant titer. The Peterson method 
uses Kolmer sal ine as a diluent with a 15 min incubation time 
and a 480 (final serum dilution) significant titers. The 
CDC method uses Veronal buffer (pH 7.3) as a diluent with a 
30 min incubation time and a 40 (initial serum dilution) 
significant titer. These two titers differ by a factor of 
3, i. e., a 1: 40 i nit i a 1 d i 1 uti on become sal: 1 20 f i na 1 d i 1 u-
tion after the complement and ox cells are added. According 
to Ha 11 IS da ta the C DC method is super i or to the Peterson 
method. 
The rationale for using the ox cell hemolysin test for 
the serologic diagnosis of infectious mononucleosis rather 
than the heterophile antibody test with absorptions is based 
on the fact that the ox cell hemolysin is not a naturally 
occuring antibody (69, 98). Although in infectious mono-
nucleosis a characteristic absorption pattern does occur 
there are a variety of other conditions in which a similar 
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pattern may occur (98). Another argument for using the ox 
cell hemolysin test is that it can be done in one test where-
as the Davidsohn technique requires three tests. Some 
laboratories perform only the sheep cell agglutination or 
only titration after absorption with guinea pig antigen. 
With both tests false negative and false positive results 
may occur. False positive reactions in the ox cell hemolysin 
test occur rarely. This test generally el iminates the false 
positive reactions which may occur in sera of patients 
affected by numerous agents which provoke a rise in non-
specific heterophile antibodies (110). 
Mason (74) and Peterson et. al. (82) bel ieve that sheep 
agglutinins and beef hemo1ysins are similar in the specifi-
city of their reactions, while ley ton (69) thinks that beef 
hemolysins and sheep agglutinins in infectious mononucleosis 
serum are different. lee et. ale (62) were unable to separate 
beef hemolysins and sheep agglutinins and interpreted this to 
mean that beef cell hemolysis and sheep cell agglutination 
are two different manifestations of the same antibody. 
Their results also indicated that although the two antibodies 
are physically inseparable they may possess different com-
bining sites responsible for agglutination and hemolysis. 
Several other workers (41, 42, 76,82) have proposed 
the cl inical laboratory use of the ox cell hemolysin test; 
however, several technical difficulties have been reported. 
These difficulties include: (1) titers have been reported 
in terms of final dilution rather than in terms of the serum 
1 7 
dilution; (2) the amount of complement used has varied; (3) 
the use of fresh complement has produced false positive 
titers in normal sera; (4) the sera have been diluted with 
sal ine containing magnesium sulfate without buffer to control 
the pH (109). 
Hall·s (47) comp~rison of the CDC and Peterson ox cell 
hemolysin tests show that the CDC method is superior to the 
Peterson method. Four of the ten laboratories using the 
Peterson method obtained positive results on two or more of 
the four positive specimens, while all eleven of the 
laboratories using the CDC method obtained positive results 
on two or more positive specimens. These differences (40% 
vs. 100%) suggest that the CDC method is better. Statistical 
significance, however, can not be determined because the 
actual results are not recorded. 
v. SHEEP CELL CAPILLARY AGGLUTJNATION SCREENING TEST (Lee, 
Davidsohn and Mih (63)) 
Lee et. al. (63) developed the capillary screening test 
for infectious mononucleosis as a result of their observa-
tion that almost 80% of the sera submitted to them would not 
require the use of the entire differential test if a simple 
screening test were available. They objected to the Paul-
Bunnell test because it only el iminated absorption and still 
required preparation of dilutions. They claim that the ad-
vantage of their test over an agglutination test is that as 
the particulate antigens are allowed to descend through the 
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small diameter column they come into contact with more anti-
bodies and the chances of aggregation of the particles is 
enhanced. 
One volume of sheep cells are put in a capillary tube 
fo1 lowed by 3 volumes of serum being careful that an air 
bubble does not separate them. The end is then sealed, the 
capillary is inverted and the cells are observed for 
agglutination. 
The reported 1.3% false negative (3 out of 227) and 
about 11% false positive (147 out of 1338). These results 
were confirmed by Bartlet and Castagno (4) when they re-
ported an incidence of false negatives of 3% (3 out of 112) 
and 11% false positive. 
VI. FORMALINIZED HORSE CELL CAPILLARY AGGLUTINATION 
SCREENING TEST (Sigler (93)) 
Sigler (93) modified the technique of Lee et. ale (63) 
by using formal inized horse cells in his capillary screening 
test. He reported only 0.68% false positive reactions (2 
out of 296) and 1.9% false negatives (5 out of 267). 
The advantages offered by this test are: stable rea-
gents, serum inactivation is unnecessary, procedure ;s 
simple and the test has fewer positives. 
VI I. ENZYME J TEST (WHll ner (122)) 
The enzyme 1 test is based on the observation by 
W~llner (122) that serum of patients with infectious mono-
nucleosis agglutinated papain-treated sheep erythrocytes in 
lower dilutions than untreated sheep erythrocytes, but the 
results with normal serum were just the opposite. Inasmuch 
as this test was positive only 69% of the time he improved 
it by absorption with treated cells and agglutination with 
both treated and untreated cells (enzyme r I test). 
An explanation for the mechanism of operation of the 
1/ 
enzyme I test was hypothesized by Wollner (122). He 
thought that sheep cells have two types of receptors, one 
specific for infectious mononucleosis and the other non-
specific, and that some of the specific receptors are not 
readily accessible to antibody. The agglutination titer 
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is the result of the combination of infectious mononucleosis 
does not contain the specific antibody and consequently has 
a lower agglutination titer. Papain treatment inactivates 
the specific receptors and at the same time exposes pre-
viously inaccessible nonspecific receptors which results in 
increased titers in normal serum and decreased titers in 
infectious mononucleosis serum. 
After evaluating the test Davidsohn (30) stated that 
it furnishes no significant information that is not available 
with the help of the presumptive test. 
V I I I. 
II 
ENZYME II TEST (Wollner (123, 124, 125)) 
In the enzyme I I test serum absorbed with papain-
treated sheep erythrocytes is then titrated with untreated 
and papain-treated cells. The infectious mononucleosis serum 
has a sheep cell agglutinatin titer 4 or more tubes higher 
with the untreated cells than with the papain-treated cells 
(30, 1 23, 1 24, 1 25) • 
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It has been proposed that in the enzyme I f test the ab-
sorption with papain-treated erythrocytes removes the non-
specific antibodies from the serum but does not affect the 
specific antibodies. Testing such serum with untreated 
sheep cel Is (having specific receptor~) will yield a titer 
at least 4 dilutions higher than with papain-treated cells 
(without specific receptors) (125). 
Davidsohn et. al. (30) reported that in their laboratory 
the differential, enzyme' I, and beef hemolysin tests 
yielded generally comparable results. 
IX. PAPAIN TREATED SHEEP CELL AGGLUTINATION TEST (Lovric 
(70) ) 
Papain has been shown to inactivate infectious mono-
nucleosis receptors on sheep erythrocytes (122), but trypsin 
does not (95). Papain and trypsin do not significantly 
affect horse agglutinin titers of infectious mononucleosis 
sera, but both enzymes increase the titers of non-infectious 
mononucleosis sera (64). 
Lovric (70) in 1961 introduced a sl ide test for infec-
tious mononucleosis using treated and untreated stabi1 ized 
sheep erythrocytes. This test was based on the earlier 
agglutination of untreated cells when compared to papain-
treated cells by serum from patients with infectious mono-
nucleosis. He later (71) evaluated this test by comparing 
it to the presumptive and differential tests. No false 
positives were reported on 620 patients. An advantage of 
this sl ide test is that the cells are reported to be stable 
for 14 months when stored at 5 C. 
x. INDIRECT FLUORESCENT ANTIBODY TEST (48, 89) 
In 1968 Henle, Henle and Diehl (49) reported the as-
sociation of antibodies to a herpes-type virus (Epstein-
Barr virus) and infectious mononucleosis. The test is per-
formed by a110wing unknown serum to react with a line of 
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EB-3 Burkitt tumor cells smeared on glass sl ides. The cells 
have been grown in an arginine-deficient medium to enhance 
the content of virus. After a110wing the serum to react the 
cells are then washed and fluorescein-labeled anti-gamma 
globul in is al lowed to react with the cells. If antibodies 
to the virus are present the fluorescein-labeled antibody 
will bind to them and can be detected with fluorescent 
microscropy. Although the EB virus is suspected of being 
the etiological agent of infectious mononucleosis, this 
hypothesis has not been proven. Indirect fluorescent anti-
body tests using the EB virus antibodies have been developed 
but they are not practical from a cl inical standpoint be-
cause of the uncertain specificity of the antibodies and 
becaus~ once a patient develops antibodies, titers remain 
elevated for years. Studies have shown (89) that nearly 
50% of adults have antibodies which will react with this 
antigen, thus making the fluorescent antibody test completely 
useless as a diagnostic tool. 
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Xl. COMMERCIAL SLIDE TESTS AND TEST KITS (33) 
As a result of the increasing demand for diagnostic 
tests and in an attempt to simpl ify and speed up testing 
procedures, a number of commercial products are now available 
for screening and testing for infectious mononucleosis 
(Table I I). Some of the tests are discussed in this work, 
others have not been discussed because of the lack of 
availabil ity of 1 iterature or the vague and incomp1ete nature 
of the available 1 iterature. 
Hall (47) has reported that commercial sl ide tests are 
re1iable for detecting moderate to high levels of antibody, 
but the low or border1 ine antibody levels can not be detected 
consistently by them. He also reported a high level of 
specificity for these tests. 
XI I. MONOTEST-DENCO TEST (Hoff and Bauer (56)) 
Stuart et. al. (102) reported that horse erythrocytes 
contained an antigen which reacted with infectious mono-
nucleosis sera. Beer (6) demonstrated that horse cells re-
acted in a manner comparable to sheep cells in infectious 
mononucleosis and serum sickness, but that titers for in-
fectious mononucleosis antibodies were higher when horse 
cells were used. In 1964 Wilkinson and Carmichael (120) 
confirmed this observation by demonstrating that in the 
course of infectious mononucleosis the agglutinin titers in 
the serum were higher with horse red cells than with sheep 
red cells. Lee, Davidsohn and S1aby (64) determined that 
agglutinin titers for horse cells of infectious mononucleosis 
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TABLE I I 







Reagents for Rapid Plate Screening 
Heterophile Antibody 
Differential & OxCe11 Hemolysin Test 
1M Slide Test Kit 
Rapid SI ide Test 
Heterophile Antibody 
Beckman Diagnostics (Diagluto 1M) 
Behring Di~gnostics 
Bio-Diagnostic Systems (Mono-phile) 
Boehringer Mannheim Cor. (Rythrotex) 
Burroughs Wellcome 
Rapid SI ide Test 
Rap idS lid e T est 
Reagents for Agglutination Test 




Rapid Slide Test 
Agglutination or Differential 
Heterol SI ide Test 
Grand Island Biological Co. 
HyJ and 
(Tekit) Agglutination 51 ide Test 
Markham Laboratories (Markam Slide 
Microbiological Research Corp. 
Microbiological Research Corp. {1M 
Organon (Monosticon) 
Organon (Monosticon DRI-DOT) 







Reagents for 1M Serodiagnosis 
Test)IM Rapid Slide Test 
Paper Slide Agglutination Test 
Kit) Rapid 51 ide Test 
Differential SI ide Test 
Rapid 51 ide Test 
Heterophile Antibody Titration 
Differential 51 ide Test, 
Mirror-Sl ide Agglutination Test 
Slide Agglutination Test 
Slide Agglutination Test 
Automated Test Materials 
Differential Slide Test 
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and non-infectious mononucleosis sera were approximately two 
dilution tubes (4 times) higher than they were for sheep cells. 
Barrett (3) had previously observed the persistence of horse 
cell agglutinins after the loss of sheep cell agglutinins in 
patients convalescing from infectious mononucleosis. Barrett 
(3) devised a test for infectious mononucleosis using horse 
cells in place of sheep cells, but his test was not superior 
to the sheep cell test. 
Cox (18) was the first to use fixed cells and Hoff and 
Bauer (56) were the first to uti1 ize formal inized horse 
erythrocytes as the antigen for a rapid sl ide test for in-
fectious mononucleosis (Mono-Test). As developed by Hoff 
and Bauer the rapid slide test for infectious mononucleosis 
consists of mixing one drop of a 4% sal ine suspension of 
formal inized horse erythrocytes with one drop of serum 
(either heated or unheated) on a flat glass sl ide, mixing 
at room temperature with a wooden appl icator stick, rotating 
the sl ide for two minutes and reading for agglutination 
within this time period using indirect 1 ighting from below 
over a dark background. Finely granular patterns are read 
as negative. Positive sera produces coarse agglutination 
which usually develops within one minute. Sal ine controls 
are included. 
This test does not require the inactivation of comple-
ment and does not require fresh cells. The cells are stable 
for at least 6 months at 4 C (56). It is sold commercially 
as the Mono-Test in the United States and as the Denco test 
in England (20, 72). 
Using the Davidsohn differential test as an arbitrary 
definition of infectious mononucleosis, Hoff and Bauer (56) 
reported that the horse cell test gave a positive reaction 
in 183 cases, while the Davidsohn differential test was 
positive in 180 cases (98% agreement). Of 80 cases with 
sheep cell antibodies but no horse cell agglutinins, four 
were positive for infectious mononucleosis with the 
Davidsohn differential test (95% agreement) (56). Of 426 
cases suspected of infectious mononucleosis the correct 
diagnosis was reached in 419 (98.5% agreement). 
Davidsohn (32) also reported that the horse cell s1 ide 
test is more specific than the sheep cell screening test 
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and closely approximates the accuracy of the conventional 
differential absorption test, supporting the claims of Hoff 
and Bauer. Hoff and Bauer (56) reported one case of serum 
from a convalescing patient which was positive by the horse 
cell test but negative by sheep cells. Eighty positive sera 
with sheep cell titers of 56 or less had negative horse cell 
tests. A number of other reports have confirmed the high 
degree of specificity and low incidence of false reactions 
reported by Hoff and Bauer (20, 32, 72, 83, 92). 
Davidsohn (32) reported that the number of false positive 
reactions encountered with the Mono-Test (0.4%) was con-
siderably less than with the sheep cel] screening test (7.6%), 
but others have reported that it gives about 4% false 
negative reactions and as many as ]5% false positive reactions 
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when performed in parallel with the heterophile antibody test 
(88). 
Lowell and Kazakaitis (72) found that the Mono-Test 
gave comparable results to the Paul-Bunnell sheep cell 
agglutination test with guinea pig kidney absorption. The 
incidence of false positive results was 0.7%. An incidence 
of 3.5% false negative tests was found in patients early in 
the course of their disease and in the convalescent period. 
They stated that Mon-Test did not become positive earlier 
than the sheep cell agglutination test (2 cases) and did 
not persist positively as long as the sheep cell aggluti-
nation titer in the recovery phase of the disease (2 cases). 
These findings are contrary to the findings of Hoff and 
Bauer (56). 
Russell et. al. (88) reported a 4% rate of false 
positives in 151 negative cases and a 15% rate of false 
negatives in 51 cases. They also stated that a rare false 
negative may occur with non-inactivated serum. 
Sheil (92) reported no fa1se negatives in 48 positive 
cases and 8 false positives in 100 negative cases using the 
Denco test. Dann (20) claimed 99% accuracy for the Denco 
test in 139 tests. He reported one false positive and one 
fals~ negative result. 
The Mono-Test appears to be more specific than the 
sheep cell agglutination test in exc1uding infectious mono-
nucleosis, although not as sensitive in detecting cases 
with low antibody titers. The Mono-Test is recommended 
because of its "specificity, speed, simpl icity, stability 
and 1 ow co s t II (7 2) • 
Carter et. al. (15) use dilutions of patients serum 
with the Mono-Test in order to report a quantitative titer 
to the physician. They reported that the Mono-Test titer 
multipl ied by a factor of 56 is equivalent to a presumptive 
sheep cell titer. 
XI I I. AUTOMATED MoNoTEST (117, 118) 
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An automated test for infectious mononucleosis has been 
developed and was recently evaluated by the Connecticut State 
Department of Health (117, 118). This method makes use of 
the Autoanalyzer system (Technicon Corp., Tarry ton, New 
York 10591) developed for the Automated Reagin Test (ART) 
for syphi1 is (75). Reagents for this test include ART sal ine 
and a tanned preserved horse cell antigen. The test can be 
performed on unheated serum at the rate of 100 samples per 
hou r. 
The evaluation of this test involved comparison with the 
ox cell hemolysin test and the Mono-Test sl ide test. Of the 
991 samples tested 317 were positive for infectious mono-
nucleosis and 674 were negative. The percentage agreement 
with the cl inical diagnosis for the automated, sl ide and ox 
cell tests were 95.9, 96.0 and 98.1 respectively. Sensiti-
vity and specificity were not calculated by the authors but 
were as follows: Automated test - sensitivity 93.7% and 
specificity 96.9%, Sl ide test - sensitivity 89.6% and 
specificity 99.0%, Ox cell test - sensitivity 97.5% and 
specificity 98.4%. 
They concluded that the ox cell hemolysin test appears 
to be the most sensitive and specific of the three test 
procedures, with the sl ide test the least sensitive and the 
automated test the least specific. The automated test 
appeared to be satisfactory as a screening test when re-
activity was confirmed by the ox cell hemolysin procedure 
(117, 118). 
XIV. MONO-OrFF TEST (Wampole) 
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This is a differential absorption sl ide test which uses 
horse kidney antigen in place of guinea pig kidney. Horse 
kidney absorption has been reported to have the advantages 
of being less expensive, requiring less antigen, exhibiting 
decreased non-specific absorption and having an end point 
which is easier to read (29). The indicator cells consist 
of "preserved, stable" (formal inized) horse erythrocytes as 
used in the Mono-Test. 
There are no data concerning the sensitivity, specifi-
city or reproducibil ity of this test. The test includes a 
positive human serum control and the manufacturer recommends 
using a 0.85% sal ine negative control. 
XV. MONOSPOT TEST (Lee, Davidsohn and Panczyszyn (65)) 
The spot test (Monospot) is a slide procedure developed 
by Lee et. ale (65) as a result of their conclusion that 
citrate preserved horse erythrocytes are superior to for-
mal inized cells in terms of speed and intensity of test 
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reactions. This test is similar to the Mono-Test except that 
relatively short-l ived citrate preserved horse cells (20% 
suspension in 3.8% sodium citrate) are used instead of long-
time usable formal inized horse cells and the sera are ab-
sorbed with guinea pig kidney or beef erythrocytes before 
addition of the horse cells. It has been reported that un-
washed, citrate preserved horse erythrocytes can be stored 
for 3 months and give stronger and quicker agglutination in 
infectious mononucleosis than formal inized horse erythro-
cytes (31). 
Wahren (116) reported that the reactivity of the Mono-
spot test was equal to the Paul-Bunnell test, with a sen-
sitivity corresponding to sheep red cell agglutination 
titers of 20 to 40. One hundred sera from 55 patients with 
cl inical1y and hemato1ogically verified mononucleosis were 
seen. Apparent false positive reactions (5-14%) were seen 
only with sera containing normal or serum heterophile 
antibodies. 
Seitanidis (91) reported that only three out of 210 
control sera (1.4%) gave false positive results with the 
Monospot test when compared with the Paul-Bunnell test. No 
false negative results were obtained. Rose and Bell (87) 
bel ieved the Monospot test to be the most accurate sl ide 
test, but they considered the Mono-Test to be close in 
accuracy. 
Basson and Sharp (S) found that con~rary to the report 
of Lee et. al. (64) the horse cells as used in the Monospot 
test were not more sensitive than sheep cells in detecting 
border1 ine positive cases. Davidsohn (31) maintains that 
if quick results are desirable, the spot test, is in his 
experience, more dependable both as to sensitivity and 
specificity than other simpl ified tests. 
The spot test does not quantitate the titer of the 
specific heterophile antibody as does the Paul-Bunnell 
reaction. However, this is of 1 ittle practical importance 
as the titer of heterophile antibody has not been found 
to correlate with the severity or duration of infectious 
mononucleosis or with the compl ications that may accompany 
or follow the disease (5). 
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Evans et. al. (40) suggested that the Monospot test 
could be used as a confirmatory test for sera giving a posi-
tive sheep cell screening test. They claimed that agree-
ment between these two tests could be considered diagnostic 
for infectious mononucleosis and would el iminate the neces-
sity of Paul-Bunnell titrations in about 86% of the sera. 
Most tests could be reported 24 hours earl ier and would not 
require titration. 
Wolf et. al. (121) reported two cases of false positive 
Monospot tests which occurred in mal ignant lymphoma patients. 
False positive reactions have also been observed in 
hepatitis (5, 116). 
"If further experience confirms the high diagnostic 
accuracy so far achieved with the horse cell test, it may 
be assumed that differential absorption techniques will 
become largely, if not completely, unnecessary for the 
routine diagnosis of infectious mononucleosis." (32) 
XVI. UNABSORBED SPOT TEST (Cabrera and Carlson (14)) 
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Lee, Davidsohn and Panczyszyn (65) designed experiments 
using preserved horse erythrocytes and treating them with 
enzymes and alcohols in an attempt to e1 iminate the absorp-
tion process but concluded that it could not be el iminated. 
They were satisfied to el iminate the centrifugation process 
by using a fine suspension of antigen which would not 
obscure the agglutination. 
Cabera and Carlson (14) developed the unabsorbed spot 
test for infectious mononucleosis by decreasing the hemato-
crit of the horse erythrocytes used in the spot test from 
20% to 7 or 8%. By so doing it became unnecessary to absorb 
the serum with guinea pig kidney antigen. They claimed that 
this simpl ified the test without altering its specificity 
or sensitivity. The commercially preserved horse erythro-
cytes remained in good condition from four to five months 
in the refrigerator. For use the cells were diluted in a 
ratio of five parts of cells to six parts of 3.8% sodium 
ci trate. 
The test is performed by placing a drop of sal ine and 
a drop of inactivated serum on an oval-marked 51 ide with a 
white background. These are then mixed and a drop of horse 
erythrocytes (hematocrit 8%) are added. This suspension is 
mixed well with a wooden applicator stick, left undisturbed 
for 30 seconds and read for agglutination (14). 
The developers claim that the unabsorbed spot test is 
as sensitive and specific as the spot test and is simpler 
to perform. 
XVI I. BACTO-HETROL SLIDE TEST (Difco) 
Although the 1 iterature provided by the manufacturer 
(34) does not specifically state what the test reagents are 
or how they are prepared, it implies that it is Lane's (61) 
modification of Lovric's (70) modification of Brumfitt and 
O'Grady's (10) enzyme differential sl ide test. The Bacto-
Hetrol Reagent P which is described as being Ita stabil ized 
erythrocyte suspension for routinely screening sera for 
heterophile antibodies as a presumptive test for infectious 
mononucleosis ll is apparently a suspension of formal inized 
or citrated erythrocytes. The Bacto-Hetrol Reagent C which 
is described as lIa stabil ized erythrocyte suspension used 
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to confirm a positive heterophile test as being that of in-
fectious mononucleosis" is probably a suspension of enzyme 
treated sheep erythrocytes. The test includes both positive 
and negative human serum controls. 
No data are available as to sensitivity and specificity. 
XVI J I. MONO-PHILE (Bio-Diagnostic Systems, Inc.) 
This test util izes "specially treated horse erythrocytes, 
color-enhanced" as the indicator cells and includes guinea 
pig kidney absorption by means of guinea pig kidney extract 
on the disposable test card. The test includes positive and 
negative controJs prepared from human serum. 
No data are available concerning sensitivity and 
specificity. 
XIX. RYTHROTEX (Boehringer Mannheim Corp.) 
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This test util ized formal inized horse erythrocytes as 
the indicator cells (19) but adds polystyrene latex particles 
which the manufacturer claims el iminates the problem of 
hemolysis of the indicator cells and difficulty in resus-
pending the cells. The instruction sheet accompanying the 
test claims that this system does not react with Forssman 
antibodies or agglutinate with those antibodies associated 
with serum sickness. No 1 iterature is cited concerning the 
results of evaluation of this test. The test kit includes 
positive and negative controls prepared from human serum. 
XX. MONOSTICON (Organon) 
Monosticon ;s a differential sl ide test which emp'loys 
a "specially prepared stable suspension of processed sheep 
erythrocyte" which have been dyed blue and includes absorp-
tion w;th both guinea pig and beef antigens. A positive 
animal serum control is included in the kit. 
The test is intended to give a positive result on sera 
which have a Davidsohn guinea pig absorption heterophile 
titer of 56 or above, but no data are available to "document 
actual specificity or sensitivity. 
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XXI. MONOSTICON ORr-DOT (Organon) 
The Monosticon Dri-Oot test uses horse erythrocytes 
(dyed) as indicator cells and includes absorption with guinea 
pig antigen only. Both cells are dried on the test card and 
are mixed with the serum, plasma or blood in steps (guinea 
pig antigen first). 
The test is intended to give a positive result on sera 
which have a guinea pig absorbed Oavidsohn sheep cell titer 
of 28 to 56, but data are not available to document sen-
sitivity or specificity of this test. 
XXII. I. M. KIT (Microbiological Research Corp.) 
According to the information submitted to the Utah State 
Division of Health by the author laboratory, this test 
util izes formal inized horse erythrocytes and does not involve 
an absorption step- Any agglutination is considered positive. 
The test kit provides both positive and negative controls 
prepared from human serum. No data are available on 
sensitivity or specificity. 
XX II r. 0 rAGlUTO I. M. (Beckman) 
Oiagluto I. M. is a slide test which utilizes a "pro-
p r i eta r y s ta b i 1 i zed h 0 r s e - ce 1 1 sub s ta nee II a san i n d i ca tor 
and includes beef and guinea pig antigen absorption. The 
kit includes a positive human control serum and the manu-
facturer recommends the use of sal ine as a negative control. 
The test can be used as either a screening test with no 
absorption or as a confirmatory test with the absorptions. 
Literature contains no reference to documentation of 
sensitivity or specificity. 
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MATERIALS AND METHODS 
I. RATIONALE BEHIND APPROACH 
In the syphil is serology evaluation survey performed 
by the Center for Disease Control (CDC) (108), large numbers 
of specimens were obtained from subjects selected according 
to exposure to the disease or other conditions which could 
give positive results. Sera from these individuals were 
placed in small tubes, numbered, and sent to laboratories 
participating in the study. This is an almost ideal method 
for performing an evaluation survey but it is rarely used 
due to the enormous costs involved and the number of per-
sonnel and institutions required. 
As an alternative to this prohibitively expensive 
procedure, it is proposed that state, federal and private 
proficiency testing programs be used to derive evaluation 
survey data. This approach necessitates some deviation from 
ideal conditions. However, the project is designed to com-
pensate for such compromise and critically needed information 
can be obtained at much less cost. 
In order to use proficiency testing data to differen-
tiate the various tests to be evaluated, emphasis must be 
placed on the borderl ine or grey areas and on possible in-
terfering conditions. Thus, paired specimens with titers 
in these areas or containing possible interfering substances 
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were included. 
Since the number of samples ordinarily used in profi-
ciency testing is limited, therefore, random sampl ing of 
patients can not be relied upon. Such a procedure would be 
unl ikely to yield significant results. To obtain signifi-
cant results the specimens must of necessity be artificially 
produced to simulate the conditions desired. 
Detailed information concerning the exact procedure 
used by each laboratory was obtained in order to evaluate 
the effect of various modifications on the performance of 
the test. To expidite obtaining this information, we sent 
a predominately multiple choice questionnaire specifically 
designed for these tests to each laboratory. Background 
information about the laboratory and the technologist was 
obtained by a similar method. 
During the year, each shipment of test sera was used as 
proficiency testing unknowns. The results were graded, 
tabulated and then reported to the participating labora-
tories along with the usual critiques and suggestions. At 
the end of the year the resul ts were combined and the 
necessary evaluation parameters were calculated. 
Results were grouped by the type of tests used and were 
subgrouped by modifications of the standard test procedure 
used. The combined data were used to calculate specificity, 
sensitivity, and reproducibil ity of each of the groups and 
subgroups. The presence, if any, of statistical difference 
among the tests for each of the parameters was determined 
by analysis of variance and appl ication of Duncan's new 
multiple mean test. 
It has been shown (108) that there is a proportionate, 
inverse relationship between sensitivity and specificity in 
serologic tests for syphil is, and prel iminary studies using 
CDC (47) proficiency testing data (Table I I J and Figure J) 
indicate that this is also true of tests for infectious 
mononucleosis. On this basis correlation coefficients were 
calculated for these two parameters. 
Sensitivity was determined by calculating the percen-
tage of positive specimens reported to be positive; speci-
ficity was determined by calculating the percentage of 
negative specimens reported to be negative; and reproduci-
bil ity was determined by calculating the percentage of 
identical results obtained on paired specimens. Within and 
between shipment reproducibil ity were determined as well 
as overall reproducibil ity. Agreement was determined by 
calculating the percentage of results identical to the 
target values. 
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Factors which might affect the reI iabil ity of a test 
were measured by segregating and tabulating the test results 
by parameters and such variables as laboratory size, techno-
logist training and experience, technologist experience with 
the particular test, and then determining if there was a 
significant difference by analysis of variance of Duncan's 
test. 
Data processing and computer programming was performed 
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by Dr. Donna Olsen of the Department of Family and Community 
Medicine at the University of Utah using the facil ities of 
the University of Utah Computer Center. 
11. RECRUITING PARTICIPANT LABORATORIES 
There are about 75 laboratories in the state of Utah 
and 66 laboratories are involved in the state1s laboratory 
improvement program. These include the laboratories enrolled 
in the various proficiency testing programs as well as re-
ference laboratories in this and other states. Of these 
laboratories over 40 participate in either state or College 
of American Pathologists (CAP) proficiency testing for in-
fectious mononucleosis. It was anticipated that at least 
50 laboratories would participate. 
Letters were sent to each laboratory sol iciting their 
cooperation (Appendix A). They were requested to indicate 
which tests they performed and would be will ing to have 
evaluated, and were asked to fill out the appropri~te 
Background Questionnaire (Appendix B) and Test Procedure form 
(Appendix C). Changing tests during the evaluation was dis-
couraged. As an incentive to participate in this program, 
laboratories within the state were given credit for satis-
faction of proficiency testing requirements for state 
approval. Also, the participating laboratories were to be 
identified in publ ications resulting from this study. 
Laboratories were coded as they are in state proficiency 
testing and results were tabulated by code numbers. Each 
TAB LE I I I 
Prel iminary Correlation of Sensitivity and Specificity 
in Tests for Infectious Mononucleosis * 
Sensitivity Specificity 
# % # % 
Beckman 58/60 96.6 ) 4/15 93.3 
Difco 27/28 96.4 7/7 )00.0 
Organon 125/1 32 94.7 31/33 93.9 
Ortho (Monospot) 394/428 92. 1 103/1 07 96.3 
Wampole (Monotest) 293/328 89.3 82/82 )00.0 
Other 35/40 87.5 6/1 0 60.0 
Total 932/1016 91.7 243/254 95.7 
# = # correct/# done 




Prel iminary Correlation of Sensitivity and Specificity 
in Tests for Infectious Mononucleosis ** 










r = -0.95 
p = 0.05 
• Beckman (/') 
92 
90 
88 90 92 94 96 
Sensitivity 
* Difco data not included in calculating correlation 
coefficient because of the small sample size. 




laboratory's code number was known only to the State Division 
of Health and the individual laboratory. A I ist of partici-
pant laboratories was publ ished but their code numbers were 
not identified. This procedure was used to encourage parti-
cipation and at the same time el iminate the fear of being 
identified as a poor performer on these tests. As an 
additional incentive, copies of the project report were 
sent to each laboratory. 
By reference to Utah state and CAP proficiency testing 
results, it was determined that the distribution of tests 
for infectious mononucleosis used in Utah could be expected 
to be approximately as seen in Table IV. This indicated 
that good comparisons could be expected from the first 
three tests, but that the others might or might not have 
enough users to give significant results. 
The questionnaires were used to determine pertinent 
background information and details concerning the performance 
of the test, which in turn was used to determine under what 
conditions the different tests could be expected to give 
satisfactory resul ts and what factors could be correlated 
with good performance. The questionnaires were designed to 
obtain the necessary data as efficiently and accurately as 
possible because it was recognized that excessive demands on 
the laboratories would be a deterrent to their participation. 
TABLE IV 
Expected Distribution of Tests for 





























11 l. PREPARATION OF UNKNOWNS 
Since maximum titers of heterophile antibodies usually 
occur during the second or third week of illness, and may 
persist for 4 to 8 weeks, this allowed ample time to obtain 
serum from positive patients screened at the State Division 
of Health. Physicians of patients with high heterophile 
titers were contacted and their cooperation was el icited in 
obtaining blood or serum samples. 
If al I 75 laboratories in the state were to participate 
in this project, and 4 ml of serum with a titer of 224 were 
required for making positive unknowns for each laboratory, 
then 300 ml of serum with a titer of 224 or an equivalent 
volume-titer combination would be sufficient. Since sera 
with titers of 1792 or above are frequently seen, only 38 ml 
or less of such serum would be enough to prepare all of the 
positives needed for this project. To provide serum for 
negative samples and diluent for positive samples, 1500 ml 
of negative serum would be required. 
Serum was used as positive only if the patient was 
determined to have infectious mononucleosis by serologic, 
hematologic and cl inical criteria. "Most authorities agree 
that the three essential criteria for confirming a diagnosis 
of infectious mononucleosis are as follows: 
I. A cl inical picture characterized by sore throat, 
exudative pharyngotonsill itis, fever, general ized malaise, 
and lymph node enlargement. Splenomegaly is present in a 
majority of the cases and hepatitis may occur, but there is 
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rarely marked cl inical jaundice. 
2. That heterophile antibodies in the serum of patients 
with infectious mononucleosis can be detected and/or measured 
s e r 0 log i ca 1 1 Y • 
3. A characteristic blood picture (110)." 
Bender (8) and Hoagland (51) have emphasized the im-
portance of adhering to these criteria, and how deviation 
from these criteria has created considerable confusion in 
the 1 i terature. 
Positive serum was collected on 12 December 1973 from a 
patient who met these three diagnostic criteria. Onset of 
illness had occurred on about I November 1973 and was 
characterized by the conditions 1 isted in Table V and Figures 
I I and I I I. 
Ideal test specimens would be those which dupl icate the 
characteristics of cl inical test specimens as nearly as 
possible. In this program, routine proficiency testing 
specimens were used but were selected in such a way as to 
provide as much test evaluation data as possible. 
Proficiency testing for immunology in Utah consists of 
four shipments of 5 specimens each, but it was necessary 
to increase this to 6 specimens per shipment for this project 
in order to obtain all the necessary data. 
The 24 specimens consisted of 12 sera (3 pools) positive 
for infectious mononucleosis and 12 negatives (3 pools). 
Equal numbers of positive and negative sera were selected in 
46 
TABLE V 
Cl inical, Hematologic and Serologic Characteristics 
of Disease in Patient Used as Source of Positive Serum 






l:!emato1.ogic (performed 15 Dec. 1973) 
White Count 12,000 cells/mm3 
Schilling Differentia,1 (31) 
40% Segmented Neutrophil ic Granulocytes (2 or more lobed nuclei) 
2% Band Cells (Neutrophils with a single lobed nucleus) 








G.P.K. Absorbed titer 
B.E. Absorbed titer 
Ox Cell Hemolysin titer (CDC Method) 









FIGURE I I 
Characteristic large atypical (mononuc]aar) 
lymphocyte in which the eccentric nucleus is 
oyal L kidney-shaped. 
47 
FIGURE I J J 
Atypical lymphocyte with irregular (scalloped) 
cell margins and pseudopodia-l ike projections. 
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order to give equal numbers of tests for calculating both 
sensitivity and specificity. All the specimens were paired 
so that as much data on reproducibil ity as possible could be 
obtained. This design resulted in 12 tests for each of the 
parameters to be measured, i.e., specificity, sensitivity 
and reproducibil ity. 
Since CDC proficiency testing data for infectious mono-
nucleosis test procedure suggests that the critical area is 
on sera with presumptive heterophile titers of 56 to 224, 
the positive specimens were in this range. The specimens 
consisted of 3 quadruplets (within and between shipment 
pairs) of 2 fold dilutions of a pool with a titer of 224. 
This resulted in titers of 56, 112, and 224. The samples 
were tested for ox cell hemolysins to verify that these 
titers were in the expected relationship to the heterophile 
titers. This insured that the ox cell hemolysin test would 
have the same level of sensitivity and specificity that it 
would be expected to have on specimens normally encountered 
in the clinical situation. 
This procedure gave a maximum number of quadruplets 
within the critical range and at the same time the quadrup-
lets have a known relationship to each other. An additional 
advantage of this technique is that titration tests can be 
used as a measure of reproducibil ity because mUltiplying 
the resultant titers by the dilution factors should result 
in identical titers. 
Inasmuch as the negative specimens were to be used to 
measure specificity, they should include sera which could 
possibly result in false positives. The Davidsohn differ-
ential test, and some kit tests, differentiate between in-
fectious mononucleosis and serum sickness or heterophile 
antibodies; therefore, inclusion of sera exhibiting these 
properties in the negative group would be desirable if 
available. Davidsohn (31) states that the only false posi-
tives encountered in his thirty plus years of experience 
with infectious mononucleosis were in patients with rheuma-
toid arthritis or Hodgkins1s disease. False positive ox 
cell hemolysin tests have been reported (47) in patients 
that have received group 0 blood with group specific sub-
stances added. If sera from such patients could have been 
obtained it would have been included. 
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A procedure used by CDC (47) in their proficiency test-
ing is to add a small amount of rabbit anti-sheep erythrocyte 
serum (hemolysin) to negative sera. These agglutinins will 
not be completely absorbed by guinea pig or horse kidney 
antigen nor by beef cell antigens. This component was in-
cluded in one pool of the negatives. It is recognized that 
these do not reflect negatives as encountered in cl inical 
practice but are designed to detect conditions which could 
give false reactions with the necessarily 1 imited number of 
specimens used in proficiency testing. 
Freezing of specimens was chosen over lyophil ization 
because of the additional sources of error introduced by the 
latter procedure. Lyophil ization would require accurate 
dispensing and reconstituting of the sample with the added 
variable of the purity and steril ity of the water used. 
Since these are not sources of error in testing routine 
specimens, it was decided to use the freezing technique. 
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The ox cell hemolysin titer of the positive serum (12 
Dec 1973) was determined to be 5120. The test was run with 
Beckman Complement Lot #310009 and diluent Lot #310805; fresh 
ox cells obtained from the Midvale Packing Company, 420 
South Main, Midvale, Utah; and freshly prepared veronal 
buffer. Known positive and negative controls were run in 
parallel. Titration was repeated at a later date with 
identical results. The heterophile presumptive titer of 
this positive serum was determined to be 896 with a border-
1 ;ne reaction in the tube with a 1 :1792 dilution. 
Pools were prepared to have titers of 56 and 112 by 
diluting 15.6 m1 and 31.2 ml respectively of the positive 
serum (titer 896) to a total of 250 ml with previously tested 
negative serum. These pools were checks to verify their ox 
cell hemolysin and heterophile agglutination titers with 
the following results: 
Ox -ce 11 Titer H.A. Titer 
1156 Titer II poo 1 160 1 1 2 
II 1 1 2 Tit e r II p 00 1 640 448 
Undiluted Positive 5120 896 
The "224 Titer" pool was made by add i ng 0.3 m1 of 
positive serum (29 November 1973) with a titer of 229,376 as 
determined by the routine titration of the originally sub-
mitted serum, to 250 ml of negative serum. 
Negative pools Nl and N2 were simply negative sera. 
Negative pool N3 was adjusted to a titer of 56 with rabbit 
anti-sheep hemolysin by the following procedure: 
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Two ml of BBL Anti-sheep Hemolysin Lot #304924 (recon-
stituted with Lot #305679 diluent) with a heterophile agglu-
tination titer of 560 plus 25 ml of rabbit anti-sheep 
hemolysin (titer 512) which was obtained from Dr_ Stanley 
Marcus of the University of Utah were combined and brought 
to a total volume of 272 ml with previously tested hetero-
phile negative serum. 
All of these pools were tested twice for heterophile 
agglutination titer and once for ox cell hemolysin titer, 
with the results shown in Table VI- Obviously the high 
titer serum was not as high as the routine titration had 
i n d i ca ted. To co r r e c t t his err 0 r 20 m 1 of "1 1 2 Tit e r" p 001 
(acutal titer 448) was added to the 11224 Titer" pool which 
resulted in 270 ml of serum with a titer of 56 and was marked 
Pl - Since the 1156 Titer" pool actually had a titer of 224, 
it was used as the pool for that titer and was marked P3-
The other positive serum was obtained by combining 75 ml 
of the "112 Titer" pool (actual titer 448) with 225 ml of 
negative serum which resulted in 300 ml of serum with a 
titer of 112 and was m?rked P2- All of the positive sera 
were rechecked several times to verify that they were the 
prop e r tit e r . 
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TABLE VI 
Titration of Serum Pools 
Pools 1st HA Titer 2nd HA Titer Ox Cell Titer 
Negativel < 7 < 7 < 10 
Negative2 < 7 < 7 < 10 
Negative with Hemolysin 56 56 < 10 
"56 Titer" 224 224 640 
11112 Titer ll .~ 224 448 1280 
11224 Titer" 7 14 20 
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All sera were steril ized by Seitz filtration directly 
into aspiration flasks. The serum was then dispensed into 
2 ml pink stoppered vacutainer tubes by means of a special, 
steril ized apparatus. This apparatus consisted of a hose 
which could be attached to the spout of the aspirator flask; 
a needle for insertion into the vacutainer tubes; a bell 
shaped glass cover over the needle to prevent bacterial 
contamination; and a clamp on the hose to control the flow 
of serum. 
The vials were labeled and frozen at -70 C. Samples 
of each pool were then thawed and tested to determine the 
effect of freezing on the titers. There were no changes. 
Samples were shipped by packing the vacutainer tubes 
in Blood Mailers #339 (Polyfoam Packers, Chicago, Ill. 60645) 
and enclosing these mailers in Human Blood Mail ing Envelopes. 
Instruction Sheets (Appendix H) and Test Report Forms 
(Appendix G were sent to all participants. Shipments were 
made through the Division of Health mail room and were all 
sent First Class. 
Table VI I shows the specimen numbers and the pools of 
serum which were used in each specimen. The P indicates a 
positive serum and the subscript indicates the pool of posi-
tive serum used. The N indicates a negative or possible 
false positive serum. 
The six quadruplets were arranged so that there are 
two within shipment pairs and two between shipment pairs for 
each quadrup1et. This allows the measurement of within 
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TABLE V J I 
Distribution of Pools Among Shipments 
1st Shipment 2nd Shipment 3rd Shipment 4th Shipment 
Spec # Pool Spec # Pool Spec # Pool Spec # Pool 
S8-1-74 N2 S8-7-74 N2 S8-13-74 Nl S8-19-74 N3 
S8-2-74 N2 S8-8-74 PI S8-14-74 N3 S8-20-74 NI 
S8-3-74 PI S8-9-74 N2 S8-15-74 Nl S8-21-74 NI 
S8-4-74 PI S8-10-74 p) 58-16-74 P2 58-22-74 P2 
S8-5-74 P3 S8 .. 11-74 P3 58-17-74 P2 S8-23-74 P2 
S8-6-74 P3 S8-12-74 P3 58-18-74 N3 58-24-74 N3 
Pool Computer # Titer 
PJ 56 
P2 2 11 2 
P3 3 224 
N) 4 Neg 
N2 5 Neg 
N3 6 Neg (Hemolysin) 
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shipment reproducibi1 ity, between shipment reproducibi1 ity 
and overall reproducibi1 ity. The specimens were assigned 
numbers by using a combination of balanced design and ran-
domization. After the balanced design was determined the 
actual pools to be included in each shipment and the numbers 
to be assigned to each were determined by reference to a 
table of random digits. 
Specimens were prepared and shipped as routine pro-
ficiency testing specimens. Four quarterly shipments of 
6 specimens were made. Instructions and Test Report forms 
(Appendices D and E) accompanied each shipment. 
The test procedures used in testing and preparation of 
the specimens were as follows: 
A. Paul-Bunnell Presumptive Test Procedure (31,60, 
80, 1 26) • 
1. Heat inactivate 1 m1 of test serum and 1 m1 of positive 
control serum of known reactivity for 30 min at 56 c. 
2 • Set up 2 set s 0 f 1 3 tub e s (1 1 x 25 mm ) ina ra c k • P 1 ace o. 4 
m1 of 0.85% saline in the first tube and 0.25 m1 in each of 
the remaining tubes. 
3. Add 0.1 m1 of the inactivated serum to the first tube, 
mix and transfer 0.25 m1 to the second tube, and so on until 
the twelfth tube is reached. Discard 0.25 m1 from the 
twe 1 f t h tub e . The s e rum d i 1 uti 0 n s are 1: 5, 1: 1 0 , 1: 20, etc. 
4. Add 0.1 m1 of 2% sheep red blood cell suspension to each 
tube, including the thirteenth, which is the control. The 
final dilutions are 1:7,1:14,1:28, etc •• Shake each tube 
to mix. 
5. I ncuba te a t room tempera tu re for 2 hr. 
6. Results are read after shaking the test tubes to resus-
pend the sediment. Check with the naked eye. If no clump-
ing is visible, place the tube horizontally on the stage of 
the microscope and read with a low power objective. 
7. Titer is the reciprocal of the highest serum dilution 
still showing agglutination. 
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8. Controls must react properly in order for the test re-
sults to be reliable. The 13th tube should show no agglu-
tination and the positive control should be within 2 standard 
deviations of its known titer. 
8. Davidsohn Differential Test Procedure (9, 31, 60, 
126) 
1. Place in a test tube (85 x 13 mm) 1 m1 of boiled guinea 
pig kidney antigen and in another test tube 1 m1 of boiled 
beef erythrocyte antigen. 
2. Add 0.2 m1 of heat inactivated serum (56 C for 30 min). 
3. Shake and incubate at room temperature for 3 min. 
4. Centrifuge at 1500 rev/min for 10 min or longer until 
supernatant fluid is clear. 
5. Remove the supernatant fluid with a capillary pipette, 
making sure not to pick up particles. 
6. Set up as many tubes (10 x 75 mm) as needed, according 
to the titer of the presumptive test. Add 0.25 m1 of 
ph y s i 0 1 og i c sal i ne ,t 0 ea ch tub e ex ce p t the fir st. 
7. Add 0.25 ml of absorbed serum to the first and second 
tubes. 
8. Mix the second tube and transfer 0.25 ml to the third 
tube, etc.. Discard 0.25 ml from the last tube. The serum 
dilutions are 1:5, 1:10, 1:20, etc •• 
9. Add O. 1 ml of 2% sheep red blood cell suspension to 
each tube. Shake well. Final dilutions are 1 :7, 1: 14, 
1 : 28, etc .• 
10. Incubate at room temperature for 2 hr. 
11. Results are read after shaking the test tubes to re-
suspend the sediment. Check with the naked eye. If no 
clumping is visible, place the tube horizontally on the 
stage of the microscope and read with a low power 
obj ect i vee 
12. Titer is the reciprocal of the highest serum dilution 
still showing agglutination. 
13. Test is positive for infectious mononucleosis if: 
A. Titer of guinea pig kidney absorbed serum is not 
more than three dilutions or tubes lower than the 
titer of the presumptive test, and 
B. Titer of beef erythrocyte absorbed serum is at 
least four dilutions or tubes lower than the pre-
sump t i vet i t e r • 
14. A positive control of known titer should be run in 
parallel with each batch of tests and control titers should 
be within 2 standard deviations of known titer to verify 
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reI iabil ity of test procedure. If test is run at a different 
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time than the presumptive or with a different batch of cells 
or sal ine, a cell control should be included and should 
produce no agglutination. 
C. Ox Cell Hemolysin Test Procedure (CDC Method) (109, 
1 10) 
1. Make a 1:10 dilution of test sera (0.3 ml serum plus 2.7 
ml buffer) in Veronal buffered sal ine and incubate at 56 C 
for 30 min. 
2. Place ten 12 x 75 mm test tubes in a test tube rack for 
each specimen plus one tube for the ox cell control and one 
for the complement-ox cell control. 
3. Add 0.5 ml of Verona1 buffered sal ine to the second 
through the tenth tube in each row. Add one ml to the ox 
cell control tube and 0.5 m1 to the complement-ox cell con-
trol tube. 
4. Add 0.5 m1 of the 1:10 dilution of inactivated serum to 
the first and second tubes of the appropriate row- Begin-
ning with the second tube (1 :20 dilution), mix and transfer 
0.5 ml to the third tube and continue through the tenth 
tube. In order to have identical volumes, discard 0.5 ml 
from the last tube. 
5. Prepare a 50% hemolytic endpoint standard by adding the 
following reagents, in the order 1 isted, to a 12 x 75 mm 
test tube: 
A. 0.25 ml of a 2% ox cell suspension in Veronal 
buffered sal ine. 
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B. 1.0 m1 of Verona1 buffered water. 
C. 0.25 m1 of diluted (1 :15) complement. 
6. Add 0.5 m1 of a 2% ox cell suspension to each tube. 
7. Add 0.5 m1 of a 1:15 dilution of complement to each tube 
except the ox cell control tube. 
8. Shake the tubes to mix the contents. 
9. Incubate the test and control tubes at 37 C for 30 min. 
10. Centrifuge the test and control tubes at 150 G for two 
minutes. 
11. Read and record results. The tube which most nearly 
matches the 50% hemolysis standard by visual inspection is 
considered the serum titer and point. 
12. Controls must react properly for test to be reliable. 
Ox cell control and complement-ox cell control must now 
show any hemolysis. The positive control should be within 
2 standard deviations of its known titer. 
13. In absence of horse serum injections, a titer of 40 or 
above is significant in 95% of patients. 
D. Veronal Buffered Sal ine (109, 110) 
1. Stock buffer solution (5 X concentrated) 
a. Combine the following in a 2 1 iter volumetric flask 










Magnesium-Calcium solution containing 1 M MgC12 and 
0.3 M CaC1 2 (20.33 gm MgC1 2·6H2o and 4.4 gm CaC1 2• 
2H2o in 100 m1 distilled water 5.00 m1 
b. Fill to the 2.0 1 iter mark with distilled water. 
Mix thoroughly. 
c. Check the pH of the stock buffer before refrigera-
tion by making a 1:5 dilution with distil led water. 
The pH of the diluted stock must be 7.3 to 7.4. If 
the pH is not in this range, discard and prepare 
fresh stock buffer. Make sure pH of water used is 
nea r 7. 
2. Gelatin-water solution. 
a. Add 1.0 gm of gelatin to 100 ml of distilled water. 
Bring to boil to insure solution of gelatin. 
b. Add 700 m1 of distilled water at room temperature. 
c. Chill in refrigerator. (This solution should not be 
held longer than 1 week to avoid contamination.) 
3. Working Verona1 buffer solution. 
a. Dilute stock buffer solution 1:5 with gelatin-water 
solution. Store in refrigerator. Working solution 
should not be stored longer than 24 hr. The pH 
must be 7.3 to 7.4. 
E. Verona1 Buffered Water (109, 110) 
1. Stock Veronal buffered water. 
a. Combine reagents in all iter volumetric flask in 
the order listed: 
Dis til 1 e d wa t e r 
Na-5,5diethylbarbiturate 
1 N Hydrochloric Acid 
300 -400 ml 
5.1 gm 
1 7 • 25 m 1 
b. Fi 11 to the 1.0 1 iter mark wi th di sti 11 ed water. 
2. Working Verona1 buffered water. 
a. Dilute stock buffer 1:5 with distilled water. 
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F. 2% Ox or Sheep Red Blood Cell Suspension (109, 110) 
1. Preparing and washing cells. 
a. Pipette 10 ml of fresh beef or sheep blood (col-
lected in equal volume of Alsever's solution) 
through a gauze filter into a 15 ml graduated cen-
trifuge tube. Fill tube with cold Veronal buffered 
sal ine and centrifuge at 600 G (2000 rev/min with 
13 cm radius or 1700 rev/min with 19 cm radius) for 
5 mi n. 
b. Carefully remove supernatant fluid and the white 
cell layer by suction without disturbing the 
erythrocytes. 
c. Fill centrifuge tube again with cold Verona1 buf-
fered sal ine. Thoroughly resuspend the cells by 
gently mixing with a pipette. Centrifuge at 600 G 
for 5 min, and repeat the process for a total of 
three washings. If the supernatant fluid is not 
colorless after the second washing, cel 1s are too 
fragile and must not be used. 
d. Resuspend the cells once more in cold Veronal buf-
fered sal ine and centrifuge for 10 min at 600 G 
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to pack the cells. 
e. Record the volume of packed cells in the centrifuge 
tube and remove the supernatant fluid. Care should 
be taken to remove as much fluid as possible with-
out disturbing the cells. 
2. Standardization of 2% cell suspension by centrifugation 
(109, 110). 
a. Prepare a 2% cell suspension by adding 1 ml of 
packed red cells to 49 ml of Veronal buffered 
sa 1 i ne. 
b. To check the density of the 2% cell suspension, 
pipette 10.0 ml into a 12 or 15 ml graduated cen-
trifuge tube and centrifuge at 600 G for 10 min. 
A 10.0 ml al iquot of a properly prepared cell 
suspension should produce 0.2 ml of packed cells. 
NOTE: The accuracy of the graduated centrifuge 
tube should be predetermined. 
c. When the volume of packed cells is under or above 
the 0.2 ml point, the cell suspension should be 
adjusted. The quantity of Veronal buffered sal ine 
which must be added to or removed from the cell 
suspension is determined by the following formula: 
Corrected volume of cell suspension = 
Actual reading of centrifuge tube X Volume of cell 
Correct reading of centrifuge tube suspension 
d. Keep the cell suspension in the refrigerator when 
not in use. Always shake the flask gently before 
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use to secure an even suspension of the erythrocytes 
which settle on standing. NOTE: Cells may also be 
standardized by using the centrifuge method des-
cribed for the Laboratory Branch Complement Fixation 
(LBCF) technique (109, 111). In the Sanborn-Fromer 
cell counter, this suspension contains 25 X 104 + 
2 X 104 red cells per mm3 • 
3. Standardization of 2% cell suspension by spectrophoto-
me te r (109). 
a. Prepare a 2% cell suspension by adding 1 ml of 
packed red cells to 49 ml of Verona1 buffered 
sa 1 i nee 
b. Pipette 2.5 m1 of this suspension into a 15 ml 
volumetric flask and fill to the mark with Veronal 
buffered water. Allow to stand for 10 min to be 
sure lysis is complete. 
c. Rea d the op t i ca 1 de n sit y (0. D.) 0 f the 1 y sed sus-
pension in a 12 X 75 mm cuvette using a Coleman Jr. 
Spectrophotometer Model 6-D set at a wave length 
of 545 1 ambda. 
d. The target value of a 2% suspension (diluted 1 :6) 
in this instrument is an optical density of 0.556 
+ 0.020. 
e. Correct the optical density by adding or removing 
buffer from the original suspension. The required 
final volume of the suspension is determined by 
the following formula: 
Corrected volume of cell suspension = 
Volume of cell suspension X O.D. obtained 
0.556 
f. Keep the cell suspension in the refrigerator when 
not in use. 
G. Reconstitution of Lyophil ized Complement (CI) 
1. Allow the diluent and the lyophilized complement vials 
to come to room temperature. 
2. Remove the crimps from the vials carefully and slowly 
to insure that the lyophilized complement does not escape. 
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3. Pipette the diluent slowly into the complement. Do not 
splash. To reconstitute 7 ml vials, pipette 5 ml of diluent. 
To reconstitute 20 ml vials pipette 15 ml of diluent. (0.75 
ml diluent per ml of original serum). 
4. Allow the complement to stand at room temperature until 
all the large clumps have dissolved. This usually takes 1 
to 2 hr. 
5. Place the complement in a 4 C refrigerator overnight. 
6. Prepare a 1:15 dilution in cold Veronal buffered sal ine 
for use in the ox cell hemolysin test. 
H. Alsever's Solution (58) 
Glucose 24.6 gm 
Na ci trate (d i hydra te) 9.6 gm 
NaC 1 5.04 gm 
Dis tilled water 1200 ml 
Adj ust to pH 6. 1 with critic acid and steril ize by 
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filtration. 
J. Guinea Pig Kidney and Beef Erythrocyte Suspensions 
( 9) 
1. 20% Guinea Pig Kidney Suspension. 
a. Keep guinea pig kidneys frozen until used. 
b. Thaw guinea pig kidneys. 
c. Wash in physiological sal ine until washings are free 
of blood. 
d. Mash into fine pulp. 
e. Make a 20% suspension of this pulp in sal ine. 
f. Boil in water bath for 1 hr. 
g. Correct the loss of water by adding water. 
h. Add phenol to a concentration of 0.5%. When stored 
in refrigerator this suspension keeps for many 
months. 
2. 20% Beef Erythrocyte Suspension 
a. Wash beef erythrocytes three times with physio10gi-
ca 1 sa 1 i nee 
b. Pack we1 J by centrifugation. 
c. Resuspend in sal ine to make a 20% suspension. 
d. Boil the suspension in water bath for 1 hr. 
e. Make up loss of water by adding water. 
f. Add phenol to a concentration of 0.5%. 
g. Store in refrigerator. 
IV. ANALYSIS OF RESULTS 
As quarterly results were obtained they were evaluated 
and appropriate modifications in the program were made as 
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necessary. When all the data had been collected it was seg-
regated by test procedure and the sensitivity, specificity, 
reproducibil ity and agreement with target values were cal-
culated for each test. Reproducibil ity was subdivided into 
intra-shipment and inter-shipment reproducibil ity. 
Within shipment reproducibil ity was calculated by com-
paring the results obtained on each of the paired samples 
within the shipment that were from the same pool. Pairs 
with identical results were given a value of one, i.e., 
positive-positive, weak positive-weak positive, negative-
negative. Pairs with opposite results, i.e-, positive-
negative and negative-positive, were given a value of zero; 
and pairs differing by half steps, i.e., positive-weak 
positive or weak positive-negative, were given a value of 
one half. Within shipment reproducibil ity is the total of 
the values given to each pair divided by the number of 
pairs, expressed as a percentage. 
Between shipment reproducibil ity was calculated in a 
similar manner except that since there was no rational basis 
for pairing the between shipment samples from the same 
pool, values were obtained for all the possible combinations 
and the total was divided by the total number of possible 
combinations and the result was expressed as a percentage. 
Since for each pool there were two samples in the first 
shipment and two samples in the second shipment, there were 
four possible combinations of pairs for between shipment 
reproducibil ity for each pool. 
Total reproducibil ity was calculated by total ing the 
values of all of the possible within and between shipment 
pairs and then dividing by the number of pairs and expres-
sing the result as a percentage. If all four specimens 
68 
from one pool were tested this resulted in six possible com-
binations. This method of calculating total reproducibil ity 
was chosen over the method of averaging the within and 
between shipment reproducibil ities in order to el iminate 
differences in total score resulting from distribution of 
results among the specimens. In other words, this system 
was chosen because it gives identical scores on results 
which differ only in the location of the result. For ex-
ample, if the results of the four samples from the same pool 
had been positive-positive on the first shipment, and 
negative-negative on the second shipment, the within ship-
ment reproducibil ity would have been 100% (2/2), the between 
shipment reproducibil ity would have been 0% (0/4), and the 
reproducibil ity would have been 33% (2/6). If the same 
results had been obtained but with different locations, e.g., 
positive-negative on the first shipment and positive-nega-
tive on the second shipment, the within shipment reproduc-
ibil ity would have been 0% (0/2), the between shipment 
reproducibil ity would have been 50% (2/4). In both cases, 
two specimens were positive and two were negative, and the 
total reproducibil ity.was 33%. If the averaging method had 
been used the total reproducibil ity would have been 50% in 
the first example and 25% in the second. 
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Sensitivity was determined by calcu1atfng the percen-
tage of positive specimens reported to be positive; specifi-
city was determined by calculating the percentage of negative 
specimens reported to be negative; and agreement was 
determined by calculating the percentage of results identical 
to the target values. 
EXPERIMENTAL RESULTS 
Due to changes with i n 1 abora tor i es, add it i ona 1 i nfor-
mation and oversights in the preperation of the question-
naire it was necessary to change some of the codes on the 
questionnaires. On all three forms (Appendices B, C and 
E) the codes for type of test were changed to the following: 
1 • B act 0 - He t r 0 1 ( D i f co ) 
2. Davidsohn Differential 
3. Monotest (Wampole) 
4. Monospot (Ortho) 
5. Monosticon (Organon) 
6. Ox Ce 1 1 Hemo 1 y sin 
7 • D i a g 1 u to I. M. ( Be c k rna n ) 
8. I. M. Kit (Micro. Research Corp.) 
9. Monosticon Dri-Dot (Organon) 
10. Mono-Diff (Wampole) 
11. Monophile (Bio-Diagnostic Systems) 
1 2. Ry th rotex (BMC) 
On the Background Questionnaire (Appendix B) the 
following changes were made: 
Registration was changed to read: 
1. A. S. C. P. (Ameri can Soci ety of Cl; ni cal Pathol og; sts) 
2. A.M.T. (American Medical Technologists) 
3. I.S.C.L.T. (International Society of Cl inical 
Laboratory Technologists) 
4. None 
Area of Maj or Interest was changed to read: 
1 • Chemistry 
2. Ba cte rio logy 
3. Serology 
4. Hematology 
5. Blood Banking 
6. Resea rch 
7 • General Medical Technology 
Type of laboratory was changed to read: 
1 • Pr i va te Hosp i ta 1 
71 
2. Government Hospital (City, County, State or Federal) 
3. Cl inic 
4. Independent Labora tory 
5. Independent Research Laboratory 
6. Mil itary Laboratory 
7. Church Hosp ita 1 
8. Public Health Laboratories 
On the Test Procedure form (Appendix C) the type of indi-
cator cells was changed to read: 
1 • Sheep (fresh) 
2. Horse (formal i ni zed) 
3. Horse (citrated) 
4. Beef (fresh)· 
5. Other 
6. Sheep ( I'processed") 
7. Horse with polystyrene latex 
Absorption was changed to read: 
1 • None 
2. Guinea Pig Kidney 
3. Beef Erythrocyte 
4. G.P.K. and B.E. 
5· Other 
6. Horse kidney and B.E. 
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On the Test Report form (Appendix E) the type of controls 
used was changed to read: 
1 • Positive 
2. Negative 
3. Positive and Negative 
4. None 
Table VI I J shows the results of this evaluation broken 
down by type of test. Monotest (Wampole) was by far the 
most frequently used test in this evaluation with Monospot 
(Ortho), Monosticon (Organon), I.M. Kit (Micro. Res. Corp.), 
Diagluto J. M. (Beckman) and Monosticon Dri-Dot (Organon) 
following in the order 1 isted. 
Of the tests used by three or more laboratories, the most 
sensitive was Monosticon Dri-Dot (Organon) and the least 
sensitive was the Ox Cell Hemolysin. The Davidsohn Differen-
tial and Diagluto I. M. (Beckman) both achieved 100% 
specificity while Monosticon (Organon) and Monosticon Dri-
Dot (Organon) received the lowest values for specificity. 
Within shipment reproducibil ity was consistently about 
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TABLE V I I I 
Evaluation of Results by Type of Test 
No.* 





















2 2. 3 1 00 . 0 1 00 • 0 1 00 • 0 
4 4.6 91.8 100.0 96.0 
27 30.7 90·7 96.3 99·0 
13 14.8 95.5 94.2 97.5 
10 11.4 92.6 87.0 96.3 
4 4.6 68.8 95.8 100.0 
8 9.1 84.4 100.0 97.9 
(MicroResCorp) 10 11.4 91.7 96.7 95. 1 
Dri-Oot ( Organon) 
Mor.o-Diff 
(Wampole) 






1 • 1 
1.1 
Total 88 100.0 
F Probability 
100.0 86.6 96.0 
100.0 100.0 100.0 
100.0 100.0 100.0 
































* indicates number of laboratory-technologist combinations (some 
laboratories had more than one technologist reporting or more than 
one tes t used). 
5 percentage points higher than the between shipment re-
p roduc i b i 1 i ty (P <. .001 ) • 
The Davidsohn differentia1 obtained the best agreement 
with target va1ues but it was not significantly better than 
the sl ide tests. Part of the reason for the poor perfor-
mance by the ox cell hemolysin test can be attributed to 
the fact that one of the three 1aboratories changed pro-
cedures during the survey and another changed personnel 
during the survey. This coupled with the fact that even 
though the Peterson method gave positive titers on positive 
specimens these titers were not above the minimum signifi-
cant level established by the author of the test. 
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There were no significant differences between any of 
the parameters for any of the tests evaluated. Figure IV 
shows the correlation between sensitivity and specificity. 
There was an inverse relationship with r = -0.70, which is 
significant (P~.02). The results were analysed by the t 
test for dependent variables which estimates the probabil ity 
that the null hypothesis (Ho r ~ 0) is valid. 
Table IX shows the distribution of tests by quarter 
and reflects changes in usage. Two laboratories changed 
from Monotest (Wampole) to Monospot (Ortho) and fol lowing 
changes were made by one laboratory each: Monotest (Wampole) 
to Monophile (Bio-Diag. Sys.), Monotest (Wampole) to Mono-
Diff (Wampole), Bacto-Hetrol (Difco) to Diagluto I. M. 
(Beckman), Monosticon (Organon) to Monospot (Ortho) and 
Monospot (Ortho) to Monosticon (Organon). One laboratory 
FIGURE IV 
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Distribution of Tests by Shipment 
1st 2nd 3rd 4th 
Test Shipment % Shipment % Shipment % Shipment % Total % 
Bacto.Hetrol (Difco) 1.8 1.8 2 3·9 1.8 2 2.3 
Davidsohn 
Differential 2 3·7 3 5.6 3 5·9 3 5.5 4 . 4.6 
Monotest (Wampol e) 21 38.9 19 35.2 17 33.3 17 30.9 27 30.7 
Monospot ( Ortho) 6 11 • 1 6 11 • 1 9 17.6 7 12.7 13 14.8 
Monosticon ( Organon) 8·· 14.8 6 11 • 1 4 7.8 5 9. 1 10 11 .4 
Ox-Cell 
Hemolysin 3 5.6 3 5.6 2 3.9 2 3.6 4 4.6 
Diagluto (Beckman) 4 7.4 4 7.4 4 7.8 5 9.1 8 9.1 
I. M. Ki t (MicroResCorp) 5 9.3 8 14.8 6 11.8 7 12.7 10 11.4 
Dd .Dot ( Organon) 4 7.4 4 7.4 4 7.8 5 9. 1 7 8.0 
Mono-Diff (Wampole) 0 0 0 0 0 0 1.8 ) • 1 
Monophile 
(Bio-Diagnostic 
Systems) 0 0 0 0 0 0 1.8 I • I 
Rythrotex 
1.8 (BMC) 0 0 0 0 0 0 1.1 
Total 54 100 54 100 51 100 55 100 88 100 
used the ox cell hemolysin test throughout but alternated 
between Monospot (Ortho) and I. M. Kit (Micro. Res. Corp.) 
as the screening test. Another laboratory started using 
Monospot (Ortho) and Monosticon (Organon) then changed to 
Monospot (Ortho) and the Davidsohn differential then to 
Davidsohn differential and Monotest (Wampole), and finally 
to the Davidsohn differential and Rythrotex (BMC). Still 
another laboratory started the evaluation using Monospot 
(Ortho), changed to Monosticon (Organon) and I. M. Kit 
(Micro. Res. Corp.) and finally Monospot (Ortho) and I. M. 
Kit (Micro. Res. Corp.). In spite of these changes noted 
over 80% of the laboratories did not change tests during 
this evaluation. 
Table X shows the percentage agreement with target 
values by quarterly shipment and shows the rise in average 
during the year. The third and fourth quarter overall re-
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sults were significantly higher (5 percentage points) than 
the first and second quarter results (P< .05) as determined 
by Istudent 1 s" t test (t = 2.47, d.f. = 211). Presumably 
this is attributable to increased proficiency which resulted 
from proficiency testing. 
Table XI shows the evaluation of results by type of 
lab 0 rat 0 r y • I nth i s ta b 1 e tw 0 mil i ta r y h os pita 1 lab 0 rat 0 r i e s 
were included in the government hospital group and research 
laboratories were included in the independent laboratories 
group. Private hospitals achieved significantly lower 
(P<..Ol) sensitivity (69.0% vs. 93.7%) than government 
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TABLE X 
Percentage Agreement by Shipment 
1st 2nd 3rd 4th 
Test Shioment Shipment Shipment Shipment Total 
Sacto-Hetrol (Difco) 100.0 100.0 100.0 100.0 100.0 
Davidsohn 
Differential 83.5 88.7 100.0 100.0 96.0 
Monotest (Wampole) 90.6 89·5 97. 1 97.1 93.0 
Monospot ( Ortho) 97.2 91.7 90.8 100.0 94.3 
Monosticon (Organon) -95.9 94.5 79.2 86.6 88.3 
Ox .. Cell 
Hemolysin 66.7 67.0 100.0 83.5 79.2 
Diagl utO 
91.8 (Beckman) 79.2 100.0 100.0 90,6 
I. M. Kit (MicroResCorp) 90.0 91.6 100.0 92.9 92.2 
Dri-Dot ( Organon) 100.0 100.0 83.5 93.4 93.3 
Mono-Diff (Wampole) 100.0 100.0 
Monophile (Bio-Diagnostic 
Systems) 100.0 100.0 
Rythrotex . (SMC) 100.0 100.0 
Average 90.5 90.4 94.5 95.7 92.4 
F Probability ·309 .594 • 134 .631 .475 
TABLE XI 
Evaluation of Results by Laboratory Type 
Percent Reproducibil ity 
Number* of total Sensitivity Specificity With i n Between Total Agreement 
Private 
Hosp ita 1 4 4.5 69.0 100.0 99.0 96.0 97.5 82.3 
Government 
Hosp i tal 25 28.4 95.3 89.6 97.4 89.6 94.7 91 .2 
C1 inic 12 13.6 93.8 99.3 97.7 90.3 95.5 96.6 
Independent 
Lab 1 2 13.6 95.2 94.0 98.7 87.4 93.5 94.7 
Mil itary 4 4.5 87.5 100.0 100.0 100.0 100.0 91 .8 
Church 28 31 .8 91 • 1 96. 1 96.9 89.5 94.8 93.4 
Pub 1 i c Hea 1 t h 3 3.4 75.0 100.0 97.3 97.3 97.3 85.0 
Tota) 88 100.0 91 .5 94.9 97.6 90.4 95. 1 92.5 
F P rob ab i 1 i t y .009 .200 .636 .686 .687 .251 
* indicates number of laboratory-technologist combinations (some laborat6r-res-hadmore than 
one technologist reporting or more than one test used). 
....... 
\.0 
hospitals, cl inics or independent laboratories. Private 
hospitals and publ ic health laboratories had significantly 
lower sensitivity (P£.OS) than government hospitals and 
independent laboratories (69.0% & 7S.0% vs. 9S.2% & 9S.3% 
respectively). Private hospitals also achieved signifi-
cantly lower (P< .OS) agreement than cl inics (82.2% vs. 
96.6%). There were no other significant differences in 
performance between laboratories in this study but there 
may have been if the number of laboratories evaluated had 
been larger. Many of the differences were substantial but 
due to small sample size they are not significant. The 
reason for the poor performance by the private hospitals 
is not known, but it may be that in an effort to obtain 
profits the quality of testing is compromised. It is pos-
sible that if the most economical tests, control procedures 
and personnel were employed and this attitude was carried 
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to an extreme in the laboratory, the qual ity of testing could 
be adversely affected. 
Table XII shows the evaluation of results by level of 
education. Technologists with a baccalaureate degree 
achieved sl ightly better agreement than did either the high 
school graduate or the technologists with masters degrees 
(92.8% vs. 90.0% and 89.8% respectively), but the differences 
were not significant. The one "technologist" with a 
doctorate did very well (100% sensitivity, specificity and 
agreement) but not significantly better than any other 
group. Here again larger sample size may have revealed a 
TABLE X f I 
Evaluation of Results by Level of Education 
Percent Reproducibil ity 
Number* of total Sensitivity Specificity With i n Between Total Agreement 
High School 10 11 .4 85.9 95.9 98.0 94.2 96.9 90.0 
B.S. 71 80.7 92.4 94.5 97.0 90.8 95.3 92.8 
M. S • 5 5.7 86.6 96.6 99.2 82.6 88.2 89.8 
Ph.D. 2 2.3 100.0 100.0 100.0 92.0 97.0 100.0 
Total 88 100.0 91 .5 94.9 97.6 90.4 95. 1 92.5 
F P robab iIi t y .410 .517 .683 .392 • 121 .601 
* indicates number of laboratory-technologist combinations (some laboratories had more than 





Table XI I I shows the evaluation of results by profes-
sional affil iation of the technologists. The two I.S.C.L.T. 
registered technologists were about 10 percentage points 
lower in agreement than the other three groups (79.5% vs. 
92.8%) but this difference was not statistically significant. 
At the .05 probabil ity level the I.S.C.L.T. technologists 
achieved significantly lower sensitivity than the other two 
professional association's members. And at the .01 pro-
babil ity level the I.S.C.L.T. technologists achieved sig-
nificantly lower sensitivity than the A.M.T. registered 
technologists. In other words the I.S.C.L.T. registered 
technologist were more likely to report a negative result 
on a positive specimen than technologists with other 
affil ration or non-registered technologists. 
Table XIV shows the evaluation of results by amount of 
experience of the technologist. Though none of the dif-
ferences were significant the results obtained by the groups 
with zero to ten years of experience were generally better 
than the results for the group with more than ten years 
expe r i ence. 
Table XV shows the evaluation of results by amount of 
experience with the particular test being used. Sensitivity 
wa s s i g n i f r ca n t 1 Y lowe r (P..(. • 0 5 ) for the g r ou p w j t h t h r e e 
or more years of experience with the test employed than for 
the other two groups (85.2% vs. 93.9%). Reproducibil ity 
within the shipment was significantly lower (P<:.05) for 
TABLE X I I I 
Evaluation of Results by Professional Affil iation of the Technologist 
Professional Percent Reproducibil ity 
Affil iation No.* of total Sensitivity Specificity Wi th i n Between Total Agreement 
A.S.C.P. 62 70.4 92.9 95. 1 97.2 90.0 94.9 93.6 
A. M. T. 5 5.7 100.0 81 .2 96.0 97·3 97.4 89.6 
I.S.C.L.T. 2 2.3 66.5 100.0 100.0 91.5 94.5 79.5 
None 19 21.6 87.3 97.4 99.2 89.4 95.4 91 .0 
Total 88 100.0 91 · 5 94.9 97.'6 90.4 95. 1 92.5 
F Probab;l ity .020 .058 .298 .686 ·555 .214 
* indicates number of laboratory-technologist combinations (some laboratories had more 




Evaluation of Results by Amount of Experience of the Technologist 
Exper i ence Percent Reproducibil ity 
in years Number7( of tota 1 Sensitivity Specificity Within Between Total Agreement 
0-2 26 29·5 92·9 93·9 98.6 91 .0 96.4 92.7 
3 - 10 49 55.7 91 . 3 96.2 97.6 89.8 95.0 93.2 
)10 1 3 14.8 89.2 91.8 96.0 90·9 93. 1 89.5 
Average 88 100.0 9 J • 5 94.9 97.6 90.4 95. 1 92.5 
F Probabi1 ity .689 .460 .255 .394 .388 .561 
* indicates number of laboratory-technologist combinations (some laboratories had more 




Evaluation of Results by Amount of Experience with the Test Employed 
Exper i ence 
Reproducibil ity with test Percent 
in years Number* of total Sensitivity Specificity Within Between Total Agreement 
o - 1 46 52.3 93.3 95·7 98. 1 91.2 96.3 93.6 
2 - 3 18 20.4 95.4 93.4 95.3 89.6 92.8 94.5 
)3 24 27·3 85.2 94.6 98.5 89.9 94.5 88.9 
Total 88 100.0 91 .5 94.9 97.6 90.4 95. 1 92.5 
F Probability .038 .682 .044 .512 • 175 • 147 
* indicates number of laboratory-technologist combinations (some laboratories had more 




the group with two years of experience with the test than in 
the other two groups (95.3% vs. 98.2%). This suggests that 
evaluations of technologist's performance needs to be an 
ongoing effort and should not be discontinued after minimum 
qualifications have been achieved. Also, it seems 1 ikely 
that continued interest in the tests being performed is an 
important factor in maintaining proficiency. 
Table XVI shows the evaluation of results by technolo-
gist's area of major interest. Agreement was significantly 
lower (P< .05) for technologists claiming general medical 
technology as their area of major interest than for tech-
nologists whose area of major interest was hematology or 
blood banking (86.4% vs. 96.5% and 95.5% respectively). 
Also, specificity was significantly lower (P<.05) for the 
genera1 medical technologist than it was for the chemists 
(88.0% vs. 100%). In general, technologists special izing 
in hematology or blood banking obtained the best results; 
with bacteriologists and serologists next and chemists and 
general medical technologists obtaining the poorest results. 
Table XVII shows the evaluation of results by the type 
of controls used. Since 96% of the tests were performed 
with at least a positive control the effect of the use of 
controls on the rel iabil ity of the test could not be deter-
mined in this study. 
Table XVI I I shows the evaluation of results by purpose 
of test use. Most laboratories (52.4%) used the same test 
as both a screening and confirmatory test. Many laboratories 
TABLE XVI 
Evaluation of Results by Technologist1s area of Major Interest 
Area of Percent Reproducibil ity 
major interest No.* of total Sensitivity Specificity Within Between Total Agreement 
Chemistry 1 2 13.6 84.7 100.0 97.9 90.2 95.6 90.4 
Bacteriology 23 26. 1 92.8 95.7 97.4 87.9 93.8 94.0 
Serology 9 10.2 91 .8 97.6 97.3 91 • 5 94.8 94.3 
Hematology 1 3 14.8 96.8 96.2 97.8 89.9 95.3 96.5 
Blood Bank 1 2 13.6 96.6 95.8 99.0 95.8 98.5 95.5 
General 19 21 .6 87.3 88.0 97.0 90.6 94.3 86.4 
Total 88 100.0 91 .5 94.9 97.6 90.4 95. 1 92.5 
F Probabi1 ity • 191 . 1 1 8 .509 .577 .567 .070 
* indicates number of laboratory-technologist combinations (some laboratories had more 
than one technologist reporting or more than one test used). 
(X) 
......., 
TABLE XV II 
Evaluation of Results by Type of Controls Used 
Controls Percent Reproducibil ity 
Used Numbe r'" of total Sensitivity Specificity Wi th in Between Total Agreement 
Positive 33 16.6 86.4 95.4 94.4 94.4 89.4 
Negative 5 2.5 90.0 90.0 93.3 93.3 93.4 
Pos & Neg 158 79.4 85.8 95.7 97.5 97.5 93.0 
None 3 1 .5 100.0 100.0 100.0 100.0 100.0 
Total 199 100 86.2 95.6 96.9 96.9 92.5 
F probabil ity .688 .675 .269 .269 .463 
* indicates number of laboratory-technologist combinations (some laboratories had more than 
one technologist reporting or more than one test used). 
00 
00 
TABLE XV I I I 
Evaluation of Results by Purpose of Test Use 
Use of Percent Reproducibil ity 
test Number"'" of total Sensitivity Specificity Within Between Total Agreement 
Screen 34 41 . 5 90.4 94.8 97.8 91 .6 95.5 9 J • 9 
Conf i rm 5 6. 1 91 .8 100.0 95,2 89.0 94.0 96.0 
Both 43 52.4 92.5 95.0 97.6 90.0 95.0 93.2 
Total 82 100.0 91 .6 95.2 97.6 90·7 95. 1 92.8 
F Probabil ity .650 .636 .510 .604 .542 .667 
* indicates number of laboratory-technologist combinations (some laboratories had more 
than one technologist reporting or more than one test used). 
co 
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(41.5%) use their tests for screening only, with the re-
mainder (6.1%) designating a particular test as a confirma-
tory test. Agreement and specificity were a 1 ittle better 
for those tests which were used as confirmatory test only, 
but not significantly so. 
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Table XIX shows the evaluation of results by technolo-
gist's confidence in the test. Most laboratories (79.8%) 
used tests in which the technologist had "good" confidence 
and none of the laboratories used tests in which the 
technologists had Ilpoorli confidence. Although none of the 
differences were significant the tests in which technolo-
gists had only "fair ll confidence performed sl ightly better 
in general than did the tests in which the technologist 
expressed IIgood" confidence. Jt may be that some skepticism 
about the rel iabil ity of the test could result in better 
performance by the test. 
Table XX shows the evaluation of results by type of 
indicator cells used. Agreement was significantly lower 
(P <. .05) for fresh beef ce 11 s than it was for fresh sheep 
cells, or the three groups of horse cells (79.2% vs. 97.3% 
and 93.5% respectively). The beef cells were significantly 
1 ess sens i tive (P'( .01) than any of the other cell types 
(68.8% vs. 92.6%). These differences are probably not due 
to inadequacy of the beef cells but to problems encountered 
during the evaluation, such as small number of laboratories 
using the beef cel I tests, changes in personnel and proce-
dures in those few laboratories and the high titer specified 
TABLE XIX 
Evaluation of Results by Technologists Confidence in the Test 
Technologist's Percent Reproducibil ity 
Confidence Number"'tc of total Sensitivity Specificity Within Between Total Agreement 
Good 63 79.8 90.6 94.7 97.7 90.7 95. 1 91.8 
Fair 16 20.2 93.8 95.3 96.9 90.8 94.8 94.3 
Poor 0 
Total 79 100 91 .3 94.8 97.5 90.7 95. 1 92.3 
F probabil ity .468 .647 .549 . 411 .646 .431 
* indicates number of laboratory-technologist combinations (some laboratories had more than 
one technologist reporting or more than one test used). 
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TABLE XX 
Eva1uation of Resu1ts by Type of Jndicator Cells Used 
Indicator Percent ReproducibilIty 
cells Nurrber* of total SensitIvity SpecifIcity WI thi n Between Total Agreement 
Sheep 
(fresh) 6 6.8 94.5 100.0 97.3 96.0 97.3 97.3 
Horse 
(formal inized) 46 52.3 90.0 97. 1 98. 1 90.6 95.1 93.0 
Horse 
(citrated) 21 23·9 97.2 92.0 96.8 89.7 95. 1 94.2 
Beef 
(fresh) 4 4.5 68.8 95.8 100.0 83.5 89.0 79.2 
Sheep 
("processed") 10 11 .4 92.6 87.0 96.3 91.4 95.9 88.3 
Horse 
wi th 1 atex 1 • 1 100.0 100.0 100.0 100.0 100.0 
Total 88 100.0 91.5 94.9 97.6 90.4 95.2 92.5 
F Probability .013 • 150 .627 .687 ·518 • 073 
* indicates number of laboratory-technologist combinations (some laboratories had more 




by the author of the Peterson procedure as necessary for a 
positive result. It is felt that the high levels of sen-
sitivity, specificity and agreement reported by other in-
vestigators (117,118) is probably more accurate. They re-
ported 98.1% agreement, 97.5% sensitivity and 98.4% specifi-
city for the ox cell test. 
Table XXI shows the evaluation of results by type of 
adsorption used. Most of the laboratories (54.5%) used a 
procedure which did not involve and adsorption, and most of 
the laboratories (75%) which used an adsorption procedure 
used both guinea pig kidney and beef erythrocytes. There 
were no significant differences among the various adsorption 
procedures. 
Table XXI I shows the evaluation of results by end point 
used. A majority of the laboratories (84.0%) used any 
visible agglutination as the end point rather than a higher 
semi-quantitative level. Probably as a result of problems 
with the ox cell hemolysin tests, the 50% hemolytic end 
point was significantly lower (P.c....05) in agreement than the 
"2+" end point (79.2% vs. 98.7%), and in sensitivity than 
the agglutination end points (68.8% vs. 92.4%). 
Table XXI I I shows the evaluation of results by the num-
ber of serologic tests performed annually by the laboratory. 
Although the differences were not significant, there was a 
gradual increase in agreement as the number of tests per-
formed increased. Specificity was significantly lower 
(P-<..05) in the group performing the lower number of tests 
TABLE XXI 
Evaluation of Results by Type of Absorption Used 
Percent Reproducibil ity 
Absorption Number,,;\- of total Sensitivity Specificity Within Between Total Agreement 
None 48 54.5 89.4 96.2 98.3 89.7 94.6 92. 1 
GPK 9 10.2 99. 1 89.6 96.0 90.0 95.0 94.3 
GPK and BE 30 34. 1 92.3 94.3 97.0 91 · 9 95.8 92.4 
HK and BE 1 • 1 100.0 100.0 100.0 100.0 100.0 
Total 88 100.0 91 · 5 94.9 97.6 90.4 95.2 92.5 
F Probabil ity .289 .489 .395 .334 .673 .637 
* indicates number of laboratory-technologist combinations (some laboratories had more 
than one technologist reporting or more than one test used). 
GPK = guinea pig kidney 
BE = beef erythrocytes 
HK = horse kidney 
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TABLE XX II 
Evaluation of Results of End Point Used 
Percent Reproducibil ity 
Number-l( of total Sensitivity Specificity Within Between Total Agreement 
Any 
68 a 9 9 1 uti na t ion 84.0 92.3 94.3 97.7 91 .0 95.4 92.6 
1+ 
aggl ut ina t ion 6 7.4 90.5 96.3 94.5 94.0 94.3 92.8 
2+ 
aggl ut i nati on 3 3.7 97.3 100.0 97·3 96.0 97·3 98.7 
50% 
hemolysis 4 4.9 68.8 95.8 100.0 83.5 89.0 79.2 
Total 81 100.0 91 .2 94.8 97·5 90.7 95. 1 92.2 
F Probabil ity .0]6 
· 587 ·312 · 499 ·305 .077 
* indicates number of laboratory-technologist combinations (some laboratories had more 
than one technologist reporting or more than one test used). 
\0 
CJ"1 
TABLE XX III 
Evaluation of Results by Number of Serologic Tests Performed Annually 
Number of Percent Reproducibil ity 
tests Number,)'{' of total Sensitivity Specificity Within Between Total Agreement 
o - 250 20 22.7 94.6 88.4 99.2 90. 1 95.4 90.0 
251 - 1000 29 33.0 89.7 95.9 97.5 94.0 96.3 92. 1 
1001 - 5000 20 22.7 88.8 98. 1 96.2 85.4 92.5 92.6 
> 5000 19 21 .6 93.8 96.9 97.8 89.6 95.8 95.5 
Total 88 100.0 91 .5 94.9 97.6 90.4 95. 1 92.5 
F Probabil ity .490 .049 .214 .252 .282 .482 
* indicates number of laboratory-technologist combinations (some laboratories had more 




than in any of the other groups (88.4% vs. 96.8%). 
Table XXIV shows the evaluation of results by the number 
of tests for infectious mononucleosis performed annually. 
S p e c j f i cit y wa s s i g n i fica n t 1 y 1 ower (P < • 05 ) i nth e 0 to 
50 test group than it was in the 51 to 500 groups (89.1% 
vs. 98.4%). The group doing more than 500 test per year 
achieved a specificity that was not significantly higher 
than the 0 to 50 test group. Reproducibil ity was signifi-
cantly lower (P<.05) in the group doing more than 500 in-
fectious mononucleosis tests per year than it was in any 
of the other groups (89.6% vs. 95.4%). It appears that 
proficiency in using these tests increases with increased 
testing to a point after which the proficiency decl ines to 
below that of laboratories performing few tests. 
Table XXV shows the evaluation of results by the number 
of technologists in the laboratory. laboratories with more 
than 5 technologists achieved significantly lower within 
shipment reproducibil ity than the other two groups at the 
.05 probabl il ity level and significantly lower than the one 
man laboratories at the .01 probabil ity lever. The one man 
laboratories obtained 99.3% within shipment reproducibility 
while the 2 to 5 man and over 5 man laboratories obtained 
97.5% and 94.5% respectively. For between shipment repro-
ducibil ity the laboratories with 2 to 5 technologists were 
s i g n i fica n t 1 y 1 ower (P < . 05 ) t han the 0 n e ma n lab 0 rat 0 r i e s 
(86.8% vs. 95.9%). The one man laboratories also achieved 
sign i f i cantl y higher (P< .05) tota 1 reproduc i b i 1 i ty than the 
TABLE XXIV 
Evaluation of Results by Number of Tests for Infectious Mononucleosis Performed Annually 
Number of Percent Reproducibil ity 
tests Number')', of total Sensitivity Specificity Within Between Total Agreement 
o - 50 29 33.0 93. 1 89. 1 97.8 92. 1 95.8 90. 1 
51 - 200 35 39.8 91 • 7 98.3 98.4 90·9 96. 1 94.6 
201 - 500 19 21 .6 91 • 7 98.7 95.9 90.6 93.8 94.6 
> 500 5 5.7 80.0 90.0 98.4 75.3 89.6 84.6 
Total 88 100.0 91 .5 94.9 97.7 90.4 95. 1 92.5 
F Probabi] ity .334 .007 .280 . 1 1 3 . 196 .089 
* indicates number of laboratory-technologist combinations (some laboratories had more· 




Evaluation of Results by Number of Technologists in the Laboratory 
Number of Percent Reproducibil ity 
technologists No. -k of total Sensitivity Specificity Within Between Total Agreement 
22 29.3 92.4 93.2 99.3 95·9 98.0 91.7 
2 - 5 36 48.0 88.4 93.7 97.5 86.8 93.3 90. 1 
)5 17 22.7 94.8 98.7 94.5 92. 1 93.4 96.5 
Total 75 100.0 91 .0 94.7 97.4 90.6 94.7 92.0 
F Probabil ity .296 .334 .007 .042 .028 . 130 
* indicates number of laboratory-technologist combinations (some laboratories had more 




other two groups (98.0% vs. 93.3%). 
Table XXVI shows the evaluation of results by the number 
of technicians in the laboratory. Agreement increased as 
the number of technicians increased, with the laboratories 
with more than five technicians achieving significantly 
better agreement (P<.05) than the laboratories with only 
one t e c h n i cia n (95. 9% v s • 87. 9 %) . Ta b leX X V, J show s the 
evaluation of results by the total number of laboratory 
personnel (technicians plus technologists). The laboratories 
with 2 to 5 people obtained significantly lower sensitivity 
(P<.05) than the one man laboratories (89.6% vs. 96.6%). 
Table XXVI' J shows the evaluation of results by length 
of time the specimen was held before testing. Specificity 
was significantly lower (P<.05) for those specimens held 
longer than one week before testing than it was for those 
tested within one week (91.5% vs. 97.1%). Reproducibil ity 
was significantly lower (P<.Ol) for those specimens held 
for 4 to 7 days before testing than it was for those tested 
before or after this time period (94.3% vs. 97.4%). 
Table XXIX shows the evaluation of results by specimen 
holding temperature. Sensitivity and agreement were sig-
n i fica n t 1 y h i g her (P < . 05 ) for s p e c i me n s w h i c h we r e he 1 d 
at refrigerator temperatures than for those which were held 
at room temperature (89.4% vs. 82.4% and 94.9% vs. 90.7% 
respectively). Reproducibil ity was significantly better 
(P<.05) for the specimens which were held at room tempera-
ture (98.2% vs. 95.5%). 
TABLE XXVI 
Evaluation of Results by Number of Technicians in the Laboratory 
Number of Percent Reproducibil ity 
technicians Number* of total Sensitivity Specificity With in Between Total Agreement 
0 27 30.7 93.2 91 .9 98.4 90.6 95.3 91 .8 
16 18.2 87.5 92.7 96.6 88.6 93.8 87.9 
2 - 5 29 33.0 90.3 97.8 97.2 91 .4 94.8 93.8 
>5 16 18.2 94.8 96.9 98.2 89.4 96.9 95.9 
Total 88 100.0 91 .5 94.9 97.6 90.4 95. 1 92.5 
F probability .474 .250 .579 .384 .641 • 1 71 
* indicates number of laboratory-technologist combinations (some laboratories had more 




TABLE XXV I I 
Evaluation of Results by Number of Personnel (Technicians plus Technologists) in Laboratory 
Number of Percent Reproducibil ity 
personnel Numbe r"l( of total Sensitivity Specificity Within Between Total Agreement 
10 11 .4 100.0 93.4 99.6 96.4 98.2 96.6 
2 - 5 40 45.4 89.2 92.6 97.7 88.8 94.6 89.6 
>5 38 43.2 91 • 7 97.7 97. 1 90.2 94.9 94.4 
Total 88 100.0 91 • 5 94.9 97.6 90.4 95. 1 92.5 
F Probabi1 ity • 11 2 • 182 .314 .289 .234 .062 
* indicates number of laboratory-technologist combinations (some laboratories had more 




TABLE XXV III 
Evaluation of Results by Length of Time Specimens Held before Testing 
Time Percent Reproducibil ity 
(Days) Number* of total Sensitivity Specificity With in Between Total Agreement 
0-3 134 62.9 86.3 96.5 98.7 98.7 92.6 
4 - 7 35 16.4 85.0 99.3 94.3 94.3 95.2 
> 7 44 20.7 85.8 91 .5 93.6 93.6 91 .3 
Total 213 100 86.0 95.9 96.9 96.9 92.8 
F probabil ity .335 .043 .001 .001 .460 
* indicates number of laboratory-technologist combinations (some laboratories had more than 




Evaluation of Results by Specimen Holding Temperature 
Temp. Percent Reproducibil ity 
(oC) Number"'" of total Sensitivity Specificity Within Between Total Agreement 
o - 15 108 53.7 89.4 96. 1 95.5 95.5 94.9 
16 - 30 93 46.3 82.4 95.2 98.2 98.2 90.7 
Total 201 100 86.2 95.6 96.8 96.8 93.0 
F probabil ity .035 .652 .046 .046 .029 
* indicates number of laboratory-technologist combinations (some laboratories had more than 




Table XXX shows the evaluation of results by specimen 
holding time times specimen holding temperature, i.e., the 
product of the effects of time and temperature. Time times 
temperature values (TxT) were obtained by the formula: 
Tx T __. 2 tempera tu re t I me x 10 
Where times are in days and temperatures are in degrees 
c. This relationship was used to reflect the common 
characteristic of many biological phenomena of approximately 
doubl ing the effect due to time with each 10 C increase in 
temperature. For example, any specimen tested on the day 
it arrived would have a time of 0 days and a TxT value of 
o regardless of the temperature at which it was held. A 
spe~imen which was tested on the day after it was received 
would have a time of 1 day and the TxT values would be 1 if 
it had been held at 0 C, 2 if it had been held at 10 C, 4 
if it had been held at 20 C, etc •• Thus, specimens held 
for 1 day at 20 C would have the same TxT value as specimens 
he 1 d for 2 da y sat lO C, i. e., 4. 
Sensitivity, specificity, reproducibil ity and agreement 
were al 1 from 2 to 6 percentage points lower in the speci-
mens with the lower TxT values than the group which was 
tested sooner and held at lower temperature, but none of the 
differences were significant. 
Table XXXI shows the cost and time involved in the 
various types of tests as reported by the participants. 
There was no significant difference between the costs and 
TABLE XXX 
Evaluation of Results by Specimen Holding Time Times Specimen Holding Temperature 
Percent Reproducibil ity 
TXT Number* of total Sensitivity Specificity Within Between Total Agreement 
o - 7 133 49.4 88. 1 97.0 97.8 97.8 93.9 
> 7 80 50.6 82.5 94. 1 95.4 95.4 90.9 
Total 213 100 86.0 95.9 96.9 96.9 92.8 
F P rob ab i 1 i t y .088 .150 .061 .061 . 1 2 1 
* indicates number of laboratory-technologist combinations (some laboratories had more than 






Reported Costs by Type of Test 
Time 
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.37 :!:. 0 .79 !. 0 
10.4 ~ 9.7 0.74 + .61 .89 ~ .50 1.61 + .55 
30.0 :!:. 7. 1 1 .94 :!:. • 26 .54:!:.. 1 2 2.48 + • 14 
6.5:!:. 2.6 .51 ±. .25 .96 ±. .52 1.46 + .44 








times reported for the Davidsohn differential and the ox 
cell hemolysin tests. There were no significant differences 
among the sl ide tests for either costs or time required. 
The tube tests cost less for material but more for technolo-
gist time than the sl ide tests. The overall costs were 
about $1.00 per test higher for the tube tests than for the 
slide tests. 
In calculating the cost of technologist's time on those 
reports in which the time was reported but no cost for 
technologist's time was reported, it was assumed that the 
average salary for a medical technologist was $675 per month 
or $0.07 per minute. Cost of technologist's time was 
calculated accordingly. 
Table XXXI I shows the results of subjective evaluation 
of tests for infectious mononucleosis as reported by the 
laboratories using the tests. Some of the evaluations are 
inaccurate and some 1 ist the same characteristic as both an 
advantage and a disadvantage. Speed and ease of performance 
were the most frequently mentioned advantages and cost and 
lack of titer capabil ity were the most frequently mentioned 
disadvantages. 
Table XXXI J f shows a comparison of the participants re-
ported titers with the establ ished target values. The ox 
cell hemolysin titers reported by the participants seem to 
be a 1 itt1e low but the target values were well within the 
two standard deviation range in each case. The ox cell hemo-
lysin titers reported by CDC correlated much more closely 
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TABLE XXX r r 
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TABLE XXX II I 
Comparison of Participants' Results with Target Values 
Davidsohn Differential 
Ox-Cell Hemolysin Unabsorbed GPK Absorbed BE Absorbed 
001 Target Test Target Test Target Test Target Test 
# 
1 80 2.00 x/~ 7.64 56 33 . 3 xl ~ 1. 4 1 >7 12.7 xl; 4.12 <7 3.00 x/~ 3. 
= 
2 160 30.8 xl:' 2.28 112 224 >14 83.9 xl!: 1.58 <7 1 . 1 8 xl';' 2. 
= 
3 320 71 .3 x/~ 2.53-;'( 224 266.4 x/~ 1.41 >28 79.2 x/~ 1.49 <7 <7 
= 
4 <10 <10 <7 <7 <7 <7 <7 <7 
5 <10 <10 <7 14 <7 <7 <7 <7 
6 <10 2.89 xl; 4.91 56 224 56 133 . 2 xl ~ 1.41 56 224 
-- -~------ ~ 
* includes four titers of 240 by the Peterson method which were converted to 80 which is 







with the target values than did those from the other two 
laboratories. Since the CDC results were from a laboratory 
using a well establ ished procedure and employing technologists 
famil iar with the test and the other two laboratories were 
using either new procedures or new personnel, the CDC results 
were considered the most rel iable. 
All of the Davidsohn differential target titers were 
well within the two standard deviation range reported by 
the participants except for those with no deviations and 
the Davidsohn differential guinea pig kidney absorbed titers 
on pool #6 which were based on only 4 titrations. 
The results of titrations were reported as mean x/f 
one standard deviation. When working with arithmetic data 
means and standard deviations are commonly expressed in the 
form x + SO. Since the distribution of values about a log-
arithmic or geometric mean is not arithmetically symmetrical, 
this type of notation is not appl icable and other more 
cumbersome methods are commonly employed. Two methods which 
are frequently resorted to are to express the standard de-
viation in terms of the appl icable ranges or to simply leave 
the mean and standard deviation in the logarithmic form and 
not express them as antilogs at all. Both of these alterna-
tives are awkward and inconvenient to use especially for 
those with little daily exposure to such manuvers. 
The simple notation used in this paper for indicating 
geometric means and standard deviations is in the form 
xG x/+ SDG which is analogous to the arithmetic x + SO. 
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In other words, the one standard deviation range includes 
all values between xG+SDG and xG x SD G• To obtain ranges 
other than one standard deviation the SDG ;s raised to the 
power of the number of standard deviations desired. For 
example, the two standard deviation range would include all 
2 - 2 val ues between xG -7 (SDG) and xG X (SD G) ; the three standard 
deviation range would include all those values between 
xG -:- (SDG)3 and xG x (SDG)3. 
Use of this simple notation makes the figures much 
easier to handle, more readily understood and easier to 
compare or use for further calcu1ations. 
One laboratory using the CDC ox cell hemolysin proce-
dure observed that some lots of dehydrated complement ex-
hibited a small amount of hemolytic activity in the absence 
of serum. Consequently, they felt that it was desirable to 
include a complement control in the experimental procedure. 
They were apparently not following the CDC procedure closely 
since it specifies the inclusion of complement-control. An 
al ternative would be to test each lot of complement before 
it is used. 
DISCUSSION 
An important area of serologic proficiency testing 
which this study begins to investigate is the relative value 
of the different procedures used in laboratories. For a 
given serologic examination the test procedures vary ex-
tensively from laboratory to laboratory. Nothing which 
resembles a standard reference procedure (except in 
syphil is serology) is in existance and there is 1 ittle if 
any information concerning the relative specificity, 
sensitivity and reproducibil ity of the various serologic 
techniques used. 
This study shows that proficiency testing can be so 
designed that the results can be used as an evaluation sur-
vey to allow collection and correlation of data concerning 
the relative efficiency of the tests used. The main problem 
to be overcome in such an endeavor is to obtain enough data 
on single pools of sera to allow confident statements to 
be made. Large pools were made and stored in small al iquots 
to be shipped and tested at different times and by different 
shipments. The resultant data gives a good idea of the 
sensitivity, specificity and reproducibil ity of some of the 
tests as they are employed in the laboratories and the effect 
of some of the variables on the performance of the tests. 
Poor response was received from the recruitions letters 
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which were mailed to potential participants. Only 20 of the 
53 laboratories which ultimately participated in the study 
responded to the letters. Most of the participants were 
recruited by means of telephone calls just prior to the 
first shipping date. Many of the laboratories indicated 
that they desired to participate but had just failed to fill 
out and return the forms. In projects of this type in the 
future it would probably be advantageous to send only a 
self addressed post card to determine which laboratories 
wanted to participate. This card should have spaces for 
indication of positive and negative responses and should be 
returned in either case. Cards not returned after a 
specified time could then be followed up with much less 
difficulty. After the 1 ist of participant laboratories had 
been establ ished, then the background and test procedure 
questionnaires could be mailed. 
Even though considerable effort was expended to make 
sure that the questionnaire was clear and unambiguous and 
the forms were designed so the data could be keypunched 
directly, these efforts met with 1 ittle success. Many forms 
were returned incomplete. In some cases all the possible 
choices were circled when the instructions clearly indicated 
"circle oneil. Often the data entered did not fit the spaces 
that were provided. These results indicate that it would 
be worth while to submit the questionnaires to extensive 
evaluation prior to use. The forms should be completed by 
the same type of people who will be using it during the 
evaluation with any problems or questions returned to the 
person designing the form. 
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Since the average values for each of the parameters 
measured was over 90% in most cases and since many labora-
tories obtained values of 100%, it was difficult to obtain 
results which were significantly different. To obtain 
significant differences on tests with performance levels 
as high as these would probably require the use of a nation-
wide proficiency testing program. 
One of the 1 imitations of this study was that very few 
of the laboratories reported titers and many did not indi-
cate weak positive reactions and as a consequence, the 
evaluation was not as sensitive as it might have been. 
Smaller differences in test performance could probably have 
been determined if more titration procedures were involved. 
A con~iderable amount of time was spent on the data 
processing phase of this project. A computer program which 
had only recently been added to the university's computer 
program 1 ibrary was used to perform the analyses of variance. 
As a result, our use of this program served the additional 
purpose of "debugging" the program. At the termination of 
the study the "debugging" was still not completed. 
A great deal of time was also spent in checking the 
original reports for internal consistency, in checking cards 
images of these reports and in correcting and verifying 
reporting and keypunching errors. These problems plus a 
number of changes in the way data were handled resulted in 
a large number of computer output products from which ex-
tractions were made. 
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This experience with automated data processing empha-
sized the importance of a close 1 iaison between the experi-
menter and the programmer. It is helpful if each is 
famil iar with the work of the other. 
SUMMARY 
Monotest (Wampole) was by far the most frequently used 
test in this evaluation (27/88 or 30.7%) with Monospot 
(Ortho) (13/88 or 14.8%), Monosticon (Organon) (10/88 or 
11.4%), I.M. Kit (Micro. Res. Corp.) (10/88 or 11.4%), 
Diag1uto I.M. (Beckman) (8/88 or 9.1%) and Monosticon 
Dri-Dot (Organon) (7/88 or 8.0%) following. 
Of the tests used by three or more laboratories the most 
sensitive was Monosticon Dri-Dot (Organon) (100%) and the 
least sensitive was the ox cell hemolysin (68.8%). The 
Davidsohn differential and Diagluto I.M. (Beckman) both 
achieved 100% specificity; Monosticon (Organon) and 
Monosticon Dri-Dot (Organon) had the lowest specificity 
(87.0% and 86.6% respectively). There was an inversely pro-
portional relationship between sensitivity and specificity 
(P<.02), i.e., as sensitivity increased specificity 
decreased. 
Within shipment reproducibi1 ity was consistently about 
5 percentage points higher than the between shipment 
reproducibi 1 i ty (P<.. .001). 
The Davidsohn differential obtained the best agreement 
with target values but it was not significantly better than 
the sl ide tests. None of the differences in tests were 
sign i fica n t • 
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Although there were a number of changes in test use, 
frequently multiple changes, eighty percent of the labora-
tories did not change tests during the evaluation. 
Performance improved during the evaluation as re-
vealed by the fact that agreement was 5 percentage points 
higher for the second half than it was for the first half 
(P<.05). Presumably this improvement was attributable to 
increased proficiency which resulted from the educational 
and corrective influence of proficiency testing. 
Private hospitals achieved significantly lower sen-
sitivity (P<..Ol) and agreement (P<.05) than other types 
of laboratory. Sensitivity was 69.0% versus 93.3% and 
agreement was 82.2% versus 92.8%. Thus, private hospitals 
were more likely to miss the serologic diagnosis in a case 
of infectious mononucleosis. 
Technologists with a baccalaureate degree achieved a 
1 ittle better agreement (92.8%) than did either the high 
school graduates (90.0%) or the technologists with masters 
degrees (89.8%) but the differences were not statistically 
significant. The one "technologist" with a doctorate did 
very well (100% agreement, specificity and sensitivity) but 
his performance was not significantly better than any other 
group. 
The two I.S.C.L.T. registered technologists were about 
10 percentage points lower in agreement (79.5% vs. 92.8%) 
than the other groups (A.S.C.P., A.M.T. and non-registered 
technologists). Sensitivity of tests run was also lower 
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for this group (66.5% vs. 92.1%). 
Experience of the technologist made 1 ittle difference 
in the results but in general the group with 3 to 10 years 
of experience performed the best, followed by the group 
with 0 to 2 years, and the group with more than 10 years 
experience did the poorest. Experience with the particular 
test being used had about the same results. Technologists 
with 3 or more years of experience with the particular 
test had significantly lower (P<.05) sensitivity (85.2% 
vs. 93.8%) than the other group. The hypothesis formulated 
from this observation is that experience enhances perfor-
m2nce up to a point after which performance deteriorates to 
a level lower than shown by those with no experience. This 
suggests that evaluations of technologist's performance 
needs to be an ongoing effort and should not be discontinued 
after minimum qual ifications have been achieved. Also, it 
seems 1 ikely that continued interest in the tests being 
performed is an important factor in maintaining proficiency. 
Most laboratories (54.5%) used a procedure which did 
not involve any absorption, and most of the laboratories 
(75%) which used an absorption procedure used both guinea 
pig kidney and beef erythrocytes. There were no significant 
differences among the various absorption procedures. 
There was no significant differences among the different 
agglutination end points and the significant differences in 
the 50% hemolytic end point was probably not due to the 
test itself. 
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Both the length of time the specimens were held before 
testi ng and the temperature at which they were hel d had an 
effect on the rel iabil ity of the test. Specificity, repro-
ducibil ity, and agreement were all lower for specimens 
held over one week before testing than they were for those 
tested within one week. Sensitivity, specificity and agree-
ment were all lower for specimens held at room temperature 
than they were for specimens held at refrigerator tempera-
tures, but reproducibil ity was higher when specimens were 
held at room temperature. When the combined effects of time 
and temperature were evaluated it was observed that all of 
the parameters were 2 to 6 percentage points lower for the 
specimens which were held the longest times and at the 
highest temperatures. 
We were unable to evaluate the effect of controls since 
96% of the laboratories used at least a positive control. 
Sl ightly more than half of the laboratories (52.4%) , 
used the same test as both screen and confirmation and many 
laboratories (41.5%) used the tests only as screens. There 
were no significant differences in tests by use, but labora-
tories that used their test as a confirmatory test had 
better agreement (96.0% vs. 92.6%) and higher specificity 
(100% vs. 94.9%) than laboratories that used the test for 
screening only or for both. 
Most laboratories (79.8%) used tests in which the 
technologists had "good" confidence and none of the 
laboratories used tests in which the technologists had 
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"poor" confidence. Although none of the differences were 
significant, the tests in which the technologists had only 
"fair" confidence performed sl ightly better in general than 
did the tests in which the technologist expressed "good" 
confidence. 
rn general, technologists special izing in hematology 
or blood banking obtained the best results, with bacteriolo-
gists and serologists next. Chemists and general medical 
technologists obtain the poorest results. It seems that 
famil iarity with the theory of serologic agglutination tests 
and some of the possible sources of error in these tests 
could be important here. 
Beef cells yielded significantly lower (P< .05) 
agreement (79.2% vs. 93.1%) than fresh sheep cells or the 
three groups of horse cells. The beef cells were also less 
sensitive (P<.Ol) than the other cells (68.8% vs. 92.6%). 
There were no significant differences in type of absorption 
or end point. 
As the number of serologic tests performed annually in 
the laboratory increased the performance increased although 
some of the differences were not significant. Similar re-
results were observed with the number of tests for in-
fectious mononucleosis performed in the laboratory, but 
there was a point after which performance decl ined. This 
could be explained by the proposal that IIpractice makes 
perfect" but if the procedure becomes monotonous the pro-
ficiency is adversely affected. 
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One man (technologist) laboratories achieved signifi-
cantly higher (P~.05) total reproducibil ity (98.0% vs. 
93.3%) than other laboratories. Agreement increased as 
the number of technicians increased, with the laboratory 
with more than five technicians achieving significantly 
better (P<.05) agreement (95.9% vs. 91.7%) than laboratories 
with only one technician. Higher levels of performance in 
laboratories with larger numbers of personnel could be 
the result of special ization. 
There were no significant differences between the 
reported cost and time requirements for the two standard 
tests, nor among the sl ide tests. The standard tests re-
quired 30.0 + 7. 1 minutes to perform and cost $2.48 + .14 
for cost of materials and technologist's time. The sl ide 
tests required 6.5 + 2.6 minutes to perform and cost $1.46 
+ .44 for materials and technologist's time. 
Subjective evaluation of the tests showed that speed 
and ease of performance were the most frequently mentioned 
advantages and cost and lack of titer were the most fre-
quently mentioned disadvantages. 
It seems that a small laboratory could do satisfactory 
serologic testing for infectious mononucleosis by selecting 
one of the sl ide tests that meet their requirements for 
cost, shelf life, titer capabil ity, etc., and using it with 
proper controls. For larger laboratories the sl ide tests 
would serve well as screens with the standard tests 
(Davidsohn differential or ox cell hemolysin) used for 
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titration when requested. 
Even though most of the parameters measured and variables 
evaluated exhibited substantial differences they were usually 
not significantly different due to the small sample size in 
some cases and large variation in results in most cases. 
This points out the need for similar evaluations using 
larger proficiency testing programs. Programs similar to 
the one described here should be conducted to evaluate 
other types of tests so that test selection can be made on 
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MEMORANDUM 
.. MEOICAL Onl\'[ 
SALT LAKE CITY, IITAII 14113 
AREA CODE 1101 
December 14, 1913 
H •• lth r'4'lhUrt ('.~.,n"'i! 
M.dJcal E .. am""" '·"tnr.·· .~ 
Nuntnlllom. ;O\dY1V,,., l .... ",:, 
.. atec PoUUitlon (.ummlhf't 
IIJlttAtI or LAIIOItA10R.l.> 
TO: All Utah ClInical laboratories, Plus Reference Laboratories 
fROM: laboratory Improvement Program 
SUBJECT: Request for PartIcipation in Evaluation of Tests for Infectious 
Mononucleosis 
The Utah State Division of Health is uncertaking a project to evaluate 
the sensitivity, specificit~ and reproducibility of the various tests used In 
the s'tate to detect infectious mononucleosis. In order to ac.complish this, 
we plan to modify the immunology proficiency testing program so that the 
additional informat ion can be obtained as \'Iell as the routine proficiency testing 
data. These modifications will include requests for laboratory and technolo-
gIst background information and details of the test procedure. 
Laboratories enrolled in the immunology proficiency testing program and 
reference laboratories will be automatically included in this evaluation survey 
sInce it will also serve to fill the proficiency testing require~nts for state 
approval. It Is hoped that these laboratories will not find the extra work 
Involved excessive and will be able to complete the required forms. 
Other laboratories within the state are requested and encouraged to parti-
eipate in thi's program on a one-time basis so that this evaluation \vill accurately 
reflect the reliability of infectious mononuc.leosis tests used within the state. 
The evaluation will consist of four shipments of six specimens. each to be 
tested for infectious mononucleosis by whatever method is routinely us~d in the 
laboratory. During the evaluation, laboratories will be coded so that only the 
Division of Health and the individual laboratories will be able to identify their 
results. At the conclusion of the stud~a project report will be sent to each 
participant summarIZIng our findings and acknowledging the rarticipation of 
cooperating laboratories. 
laboratories willing to particIpate in this project should fill out the 
enclosed Background Questionnaire and Test Procedures forms and return them to 
the Division of Health. If more than one test is used in the laboratory. co~olete 
one Test Procedure form for each test. The only other information required w!11 
be the Test Reports to be completed upon receipt of each shipment of specimens. 
If tests used or technologist performing the tests are changed during the 
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course of this study it wil' be necessary to update the Background Questionnaire 
or Test Procedure form applicable. 
We hope that you will be able to cooperate in this study since it is 
designed to provide critically needed informati~n which will permit decisions 
concerning test selection to be based on reliable evaluation results. 
Please complete an'd return the enclosed forms as SOf>n as possible. If 
you have any questions concerning this program please contact me. 
SIncerely. 
~~ ?,~~?L-
Roger N. Taylor. Microbiologist 







(d rc:1e one) 
(Co-t. 3) 
Lab. name' _______ _ 
I. Pau)-Bunncl Presurptive 
2. Davidsohn Differential 
3. r~notest (Vampolc) 
,.. tionospot (Ortho) 
5. Honosticon (Organon) 
6. Ox-cell Hew.olysin 
7.' Diagluto I.M. (Beckman) 
e. I • H. Kit (I-Ii c ro. Sc • ) 
9. Other (specify) 
Technologist performing test --,.----""t---
(Co J. 4) (name) 
Formal education 
(circle one) 1. High school 
(Col.5 } 2. B.S. 
3. H.S. 
,.. Ph. D. 
1. ASCP 
2. MIT 
Reg is t rat ion 
(el rc1e one) 
(Col. 6) 
3. Other (specify ___ _ 
Ie. None 
Years of experience (Col. 7-8) 
Area of major interest -
(el rcle one) 1. Chemi stry 
(Col.9 ) 2. Bacteriology 
" 3. Serology 
4. Hematology 
5." Blood banking 
6. Other (specify) 
Type of laboratory 
(e I rei e one) 










5. Other (spe~ify ___ _ 
D.1te _______ _ 
Number of technologists In laboratory __ __ 
( Co 1. I I - 12 ) 
Number of technlcrans In laboratory 
(Col. 13-:1") 
tlumber of serologic tests performed in 
laboratory per year 
(Co I. 15-18) - - - --
Nurr.bcr cif tests for I.H. performed In 
laboratory per year 
(Col. 19-22) - - ---
Col. 80 • 2 
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'TEST rr,OCEOURES 
(AnS\,ler a JTa"PPTi co'lb ICques t Ions) 




Name ______ _ 
(Col. 3) 
1. Paul-Bunnell Presu~ptive 
2. Oavidsohn Differential 
3. Monotest (11.:r-pole) 
It. lionospot (Ortho) 
5. Monosticon (Organon) 
6. Ox-cell He~~lysin 
7. Diagluto I.M. (Beckm,:ln) 
B. I.H. Kit (Micro. St.) 
9~ Other (specify) 
Type of indicator cells 
(circle one) 1. Sheep (fresh) 
(Col. q) 2. Horse (formalinized) 
3. Horse (citrated) 
Absorption 
(el rcl e one) 
(Col. 5) 
Cell suspension 
t' di lution I: 
Diluent 





". Beef (fresh) 
S. Other (specify) 
I. None 
2. C~inca pig kidney 
3. Beef Erythrocyte 
". G.P.K. and S.E. 
5. Other (sped fy) __ _ 
t (Co l. 6-·7) 
(Col. 8-9) 
I. Sal inc 
2. Ve rona I Duffer 
3. Other (specify) 
Initial dilution 1: 
Ratio (2 fold, 10 fold,etc.) 
fold 
Incubation time min. (Col. 15-16) 
Incubation temp.-- • C (Col. 17-18) 
Refrigerator time - - hrs. (Col. 19-20) 
Refrigerator temp.-- • C (Col. 21-22) 
Centrifuge time - min. (Col. 23-2q) 
Centrifuge speed-- 91S x 100 (Col. 25-26) 
Ceotd fuge I of t ime~ _ (Col. 27-28) 
Date ______ -
End point reaction 
(circle one) 1. Any agglutination 




6. ~ot hemolysis 
7. 100% hemolysis 
8. Other (specl fy) ___ _ 
Dilutions reported 
(circle one) 1. Initial (before cells .:l~;'.c: 
(Col. 30) 2. Final (after cells Cldce':) 
Significant titers 
Use of test 
(Ci rclc one) 
(Col. "0) 
Unabsorbed {Col. 31-
G.P. Abs. - - - (Col. 31,. 




Number of years of p.xperlence with this 
test __ (Cel. ql-42) 
Tethnologists confidence in this test 
(el rcle one) I. Good 
(Col. "3) 2. Fair 
3. Poor 
Estimated cost per te~t for ~aterlals $ ____ (Col. ljq-47) 
Estimated cost per test for tech. time 
$ _ _ _ _ (Col. q8-51) 
Average tech. time required for one test 
min. (Col. 52-53) 
Advantages of this test (list) 
Disadvantages of this test (list) 
Col. Co '" I 
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INrOR~L>\TIO!'-! A!m INSTlUlCTlO}l !'HI-'RT FOR 
UTAH STATE nIVI~rml OF HEAl.TH 
PROnCn:::CY TESTJ~G SANPLES AND 
EVALUATION Sl1iWEY 
INFECTIOUS }!O~;o~mCLr:05IS 
1. This series of speci~ens js to be tested for infectious mononucleosis. 
2. Please test tllese specimens using l!lethod currently employed by yqur 
laboratory. 
3. Have reports s1rined by both the person performing the examination and 
by the supe~visor. 
4. Forward reports to this offjce by May 'D,l974. 
S. Please indicate the following on the enclosed report formes). 
~. Positive or negative reactions for each speci~en submitted 
and the titer f~r each positive specimen if a titration procedure 
is done in your laboratory. 
b. Please cor-plete and return the appropriate Test Procedures 
Form and/or Background Questionnaire if they have not previously 
been submitted to the Utah State Division of Hc.olth for Lt.e pro-
cedure and/or technolo~ist performing-this set of tests. If ~ore 
than one test is used. a ~eparate Test Procedure Fo~ should be 
completed for each. If ~ore than one technologist perfor~s tests 
in this pro8ram. a Background Questionnaire should be co~plcted 
for each. If we already have this information. these forms need 
not be filled out. 





Date _______ _ 
Laboratory No. 
(Col. 1-2) 
laboratory name ______________ _ 
Test employed: (circle one) 
(Col. 3) I. Paul-Bunnell Presumptive 
2. Davldsohn Differential 
3. Monotest (Wampole) 
4. Monospot (Or tho) 
S. Monosticon (Organon) 
6. Ox-cell Hemolysin 
7. Diagluto I.M. (Beckman) 
8. 10M. Kit (Micro. Sc.) 





Date specimen received: (Col. 6·9) 
day- month 
Date specimen tested: (Col. 10-13) 
day- month 
Controls used: 1. Positive 
{Col. 14) 2. Negative 
3. Positive and negative 
HoldIng temperature • C. (Col. 15-16) 
RECULTS J 
IUO not use 
this space. 
TITERS Office use 
jonly Specimen I Unabs. G.P. Abs. S.L t.bs. 
I: 1: I: 
{Col. In (Co 1-:- 18:-21) (Col. 22 :is) (C01.-26-'30) 
, I : 1: I: 
---- ----(Col. 32 (Col. 33-36 (Col.37-40 ) (Col. 41-44) 
I: I: 1: 
-------- ----(Col. '46 (Col. 47-50 (Col. 51-54} (Col. 55-5S) 
1: I: 1: 
(Col. 60) (Co 1-:- 61 =-64' (Co1.-65-68 i (Col. -69-72) 
I: 1: I: 
(Col. 74) (Cpl. 7~-7C :':(Col. 5-3) (col. 9-12) 
t: 1: I: 
----(Col. 14) ---- ----(Col. 15- i S~ (col. 13· ::.2) (Col. 2~-26) 
* Dup. Col. 1-4 
I NTEP.PRETATI O~; 
,':')Pos,or_~ 




(Co 1. 13) 
(Col. t:;) 
Col. ao • 3 
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List of Participant Laboratories 
I. W. Allen Memorial Hospital 
719 West 4th North 
Moab, Utah 84532 
Beaver Valley Hospital 
85 North 400 East 
Beaver, Utah 84713 
Budge Cl inic 
225 East 4th North 
Logan, Utah 84321 
Carbon County Hospital 
Washington Park 
Price, Utah 84501 
Cottonwood Hospital 
5770 South 3rd East 
Murray, Utah 84121 
Duchesne County Hospital 
26 West 2nd North 
P.O. Box 698 
Roosevelt, Utah 84066 
General Health Systems 
4500 South 1900 West 
Roy, Utah 84067 
Holy Cross Hospital 
1045 East 1st South 
Salt Lake City, Utah 84102 
Intermountain Laboratories, Inc. 
870 East 7200 South 
Midvale, Utah 84047 
Logan LDS Hospital 
218 North 3rd East 
Logan, Utah 84321 
Medical Center Laboratory 
508 East South Temple #120 
Salt Lake City, Utah 84102 
Neighborhood Health Center 
127 East 21st South 
Salt Lake City, Utah 84115 
American Fork Hospital 
350 East 300 North 
American Fork, Utah 84003 
B rig h am Me d i cal C 1 i n i c , J n c . 
1400 North 1st East 
Brigham City, Utah 84302 
B.Y.U. Student Health 
Brigham Young University 
Provo, Utah 84601 
Cooley Memorial Hospital 
40 North 1st East 
Brigham City, Utah 84302 
Dixie Memorial Hospital 
551 South 300 East 
St. George, Utah 84770 
Fi~lmore LDS Hospital 
25 South 100 West 
Fillmore, Utah 84631 
Gunnison Valley Hospital 
P.O. Box 354 
Gunnison, Utah 84634 
Intermountain Cl inic 
699 East South Temple 
Salt Lake City, Utah 84102 
Juab County Hospital 
549 North 4th East 
Nephi, Utah 84648 
McKay-Dee Memorial Hospital 
3939 Harrison Avenue 
Ogden, Utah 84403 
Microbiological Research Corp. 
481 South 400 East 
Bountiful, Utah 84010 
Ogden Clinic 
2955 Harrison Avenue 
Ogden, Utah 84403 
Panguitch LDS Hospital 
145 East Center 
Panguitch, Utah 84759 
Pathology Associates Laboratory 
1965 East 5600 South 
Salt Lake City, Utah 84121 
Primary Childrens Hospital 
320 12th Avenue 
Salt Lake City, Utah 84103 
St. Mark's Hospital 
1200 East 3900 South 
Salt Lake City, Utah 84117 
Salt Lake LDS Hospital 
325 8th Avenue 
Salt Lake City, Utah 84103 
Sevier Valley LDS Hospital 
201 East 500 North 
Richfield, Utah 84701 
Tanner Memorial C1 inic 
312 Gentile 
Layton, Utah 84041 
Uintah County Hospital 
175 North 1st West 
Vernal, Utah 84078 
U.S.A.F. Hospital 
Hill Air Force Base 
Clearfield, Utah 84406 
Utah State Training School 
P.O. Box 8 
American Fork, Utah 84003 
Valley View Medical Center 
595 South 75 East 
Cedar City, Utah 84720 
Veterans Administration Hosp_ 
500 Foothill Drive 
Salt Lake City, Utah 84113 
West Millard Hospital 
275 West 100 South 
Delta, Utah 84624 
133 
Para Diagnostics Laboratory 
2180 East 4500 South 
Salt Lake City, Utah 
Physicians C1 inica1 Laboratory 
2036 South 13th East 
Salt Lake City, Utah 84105 
St. Benedict's Hospital 
3000 Polk Avenue 
Ogden, Utah 84403 
Salt Lake Cl inic 
333 South 9th East 
Salt Lake City, Utah 84102 
San Juan Hospital 
384 West 3rd North 
Monticello, Utah 84536 
South Davis Community Hospital 
401 South 400 East 
Bountiful, Utah 84010 
Tooele Valley Hospital 
211 South 1st East 
Tooele, Utah 84074 
University Medical Center 
50 North Medical Drive 
Salt Lake City, Utah 84112 
U.S. Army Hospital 
Dugway Proving Ground 
Dugway, Utah 84022 
Utah Valley LDS Hospital 
1034 North 5th West 
Provo, Utah 84601 
Valley West Hospital 
4160 West 3400 South 
Granger, Utah 84102 
Wasatch Laboratories 
211 Medical Arts Building 
Salt Lake City, Utah 84110 
Referee Laboratories 
Center for Disease Control 
Microbio1ogy and Serology Unit 
Atlanta, Georgia 30333 
Department of Health & Environmental Sciences 
Laboratory Division 
Helena, Montana 59601 
Utah State Division of Health 
Serology Section 
Salt Lake City, Utah 84113 
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Bo"'o' If •• llh DIVISION OF HEALTH All Conwft'.ai .. u\ C-D",., ....... 
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MEMORANDUM 
U MEDICAL DRIVE 
SALT LAKE CITY, UTAII8UU 
",altA CODE tOI 
328-6131 
January ", 197" 
H.llth F."hu#1 C:-'Ufltll 
Mc4ic&l tWIMU", t.,.UIt'! ....... ~·"!' 
NUlIl", H('Itnt Ad".".,.· (,,", ,,;J 
W.c.r 'oU\ltioft Con.mu:..t 
.VUAU OF LAlOP;4TUIUr-
TO: Partlcipants, Immunology Proficiency Testing Program and Infectious 
Mononucleosis Test Evaluation Program 
fROM: Laboratory Improvement Program, Bureau of l~boratories 
SUBJECT: Shipment No. I, 1974, Infectious Mononucleosis Testing 
Under separate cover we are ser.d!r.g six (E) speci~ens for examina-
tion as part of the Utah State Proficiency Testing Program. The 
specimens should be examined and the results reported to this office 
no later than January 21, 1974. 
An Instruction sheet will be enclosed with the specimens. \Ie \0·:;11 also 
send two report forms in order that you may retain a copy for your files. 
A report of the findings of the reference laboratories and the partt· 
clpant laboratories will be forwarded upon receipt of the results. 
Sin~eJ}Y' Cf7t~~ ;;!. ~-&"- t~~ 
John L. Clayton, Hicr biologist 
JLC/eh 
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DIVJSJO~ OF HEALTH 
U MEllICAL DIUV£ 
• ALT LAKE CITY. UTAH "11.1 
AREA CODE 1101 
Air Conut'\ a!u"'n COf"'1.~ ,-tu 
J..,.lth r .. rl!\h:tl c,,~ ..... 
1d~4.c.u l;;"."I'unf't CIl",:".::"" 
Nl.lninr: ltor.1e" Ar;h,·-.~I: l.'lIHlt':J 
9,'''Uf 'olhaloQ C.·:mlt~::,'1 
LTMA. I. OLSUI. ".D •• W.,..IL 
..... n. .t H ... tU. 
328-6131 
tUII£AIJ or LABORATC'·;"[s 
February 6, 1974 
ME HORAflOUH 
TO: Participants, l~unolo9Y Proficiency Testing Program and Infectious 
~ononucleosjs Test Evaluation Program 
FROM: .laboratory Improvement Program, Bureau of laboratories 
SUBJECT: I: H. Test Results - Shipment No. I, 1974 
On 7 January 1974 six Infectious mononucleosis test evaluation and pro· 
ficiency testing specimens \O/ere shipped to participating laboratories. Table 
I shows the results obtained by e~ch laboratory and their score. 
The target values for these samples were as follows: 
Specimen no. Sl ide Tests Ox-Cell Hemolysin Davidsohn Di fferent t al 
(CDC l'1ethod) ~. G.P.K. i,bs. B.L 
SB-1-14 and 
S8-2-14 Neg .c: to <: 7 <.7 <7 
SB-3-74 and 
SB·"-7~ Pos 80 56 ~ 7 <7 
58-S-7!' and 
S8-6-74 Pos 320 224 ~ 28 "-.7 
;"bs. 
For state approval in immunology, laboratories are required to cbtain at least 
7S% agreement with referee laboratories. In this set of specimens the referee 
laboratories (lab. Nos. 70, 71, and 72) received an average grade of 77.7%. There-
fore, the minimum acceptable grade for state approval on this ship!':",ent is 75:': of n.;:;, 
or 58.3%. All laboratories received accepta~le scores due to the poor perforl':"ance of 
the referee laboratories. Of the 50 test reports returned, 35 received 9ra~es of 
loot; 4 received 9ra~es of 83t and 11 received grades of 67%. The Dverase (rean) 
grade was 9D.9~. The average score with the standard tests (Davidsohn Differential 
and Ox-Cell He::lolysin) vIas ae.o;; while the average score for the slide tests was 
92.U. 
All of the errOl'lu::.;t; re~ultS vlere reported 'on spccir:ens sa-3-74 and S8-it-74 
which were made from [he sa:"le pool and were; intended to be borderline positives. 
- 1 -
Of the test reports on these two specimens 51.0t were positIve. 21.6% were weakly 
positive and 27.~~ were neg~tive. 
Laboratories are encourD;ed to revieu thei r procedures to verify that they are 
performed in accordance with the author's or manufacturer's directions and that proper 
controls are included. 
Your participation in this program is appreciated. If there are any questions 
concerning the program or your results please contact us. 
Sincerely. 
CJrt, ;!~;,b:~ 
~hn L. Clayton. Micr~biologist 






I mlllunol o(]y Proficiency Testinq and Infectious t'.ononucleosis Test EvaluaticnResults 
Sample Nos. SB-l·7" SB-2·7q SB·3-7~ SB-"·7~ SB-5-74 SB-6-7" 
Lab. Nos.. Score:' 
1 Neg Neg Pas Pos Pos Pas; 100', 
2 Neg Neg W. Pos V. Pas Pas Pos 100 
3 Neg Neg V. Pas Neg Pos Pos 63 
.. Neg Neg Pas Pas Pas Pos 10v 
5 Neg Neg Pos Pos Pos Pos 100 
6.2 Neg Neg Pos Pos Pos Pos 100 
6.3 Neg Neg Pas Pos Pas Pos 100 
7· Neg Neg Neg Neg POl Pas 67 
8 Neg Neg Pas Pos Pas Pos JOO 
11 Neg Neg Pos Pos Pas Pas 100 
12." Neg Neg W. Pas W. Pos Pos Pas 100 
12.6 Neg Neg Neg Neg W. Pos W. Pas 67 
13 Neg Neg Neg Neg Pos Pos 67 
IIf Neg Neg Pos Pos Pos Pos 100 
15 Neg Neg W. Pas W. Pos Pos Pos 100 
17 Neg Neg Pos Pos Pas Pos 100 
19 Neg Neg Pas Pos Pos Pos 100 
20 Neg Neg Pos Pos Pos Pos JOe 
22 Neg Neg Pos Pas Pos Pos 100 
23 Neg Neg W. Pos W. Pos POl Pas 100 
2S Neg Neg Pos Pos Pos Pos 100 
26 Neg tleg Neg Neg Pos Pos 67 
27 Neg Neg Pos Pos Pos Pos 100 
31 Neg Neg Neg Neg Pos Pos 67 
32 Neg Neg· Neg Neg Pos Pos 67 
34.4 Neg Neg Pos Pos Pos Pos 100 
31,.51 Neg Neg Pos Pos Pos Pos 100 
3~.52 Neg Neg Pos Pos Pos Pos 100 
36 Neg Neg W. Pos W. Pos P05 Pos 100 
39 Neg Neg W. Pos W. Pos Pas Pos lOa 
40 Neg Neg Pos Pos Pos Pos 100 
43 Neg Neg Neg Neg Pos Pos 67 
It" f~ag Neg Neg W. Pos Pos Pos 83 
It6 Neg Neg Neg Neg Pos Pos 67 
It7 Neg Neg W. Pos W. Pas Pos Pos 100 
51 Neg Neg W. Pos \I. Pos Pos Pos 100 
52 Neg Neg W. Pos. Neg Pos Pos 83 
53 Neg Neg Neg Ncg Pos Pos 67 
51f Neg Neg Pos Pos Pos Pos 100 
56.31 Neg t~eg Pos Pos Pos Pos lCO 
56.32 Neg Neg V. Pos W. Pos Pos Pas 100 
58 Neg Neg Pos Pos Pos Pos 100 
S9 Neg Neg Pos Pos Pos Pos laC 
.. 3 .. 
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TABLE I (cont I d) 
Sam"le Nos. 5B-'-74 58-2-74 58-3-74 5B-4-74 5B-5-74 S8-6-74 
Lab. Nos. Sc.:>re·· 
61 Neg Neg Pas Pas Pas Pas lC:~ 
62 Neg Neg Pas Pos Pas Pas ,e:. 
63 Neg Neg' Neg W. Pas Pas Pos £3 
64 Neg Neg Pas Pos Pas Pas lC~ 
6S Neg Neg Neg tleg Pos Pos 67 
70 Neg Neg Pos Pos Pas Pos Ie:> 
71 Neg Neg Neg Neg Pos Pas 67 
72 Neg Neg Neg Neg Pos Pos ~ 
X • 9~.9~ 
* Request for repeat of questionable results were tabulated as w. pas. 
Your I?boratory code number is ___ _ 
- " -
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April 3, 1974 
TO: Participants, In~unclogy Proficiency Testing Program and Infectious 
l-!ononuc1eosis 'Lest Evaluation Program 
FRO!-I: Bureau of Laboratories, Laboratory Improvement Program 
SUBJECT: I. M. Test Results - Ship~ent No.2, 1974 
On J.1arch 4, 1974 six infectious mononucleosis test evaluation and profici(':nc>' 
testing speci!r.ens were s!lipped to participatinr; laboratories. Table 1 shO' .. s the 
results obtained by each laboratory and their score. 
The target values for these samples ~ere as follows: 
Specimen So. Slide Tests Ox-Cell Henolysin Davidsohn Dif~ercntial 
(CDC ~~et~ocl) ~ G.P.I:. . !.:'s. P ... E • ,,! .. :- ~. 
SB-7-74 and 
58-9-74 Neg < 10 < 7 < 7 < 7 
S8-8-74 and 
58-10-74 Pos 80 S6 ! 7 < 7 
SB-1l-74 and 
! 28 SB-12-74 Pos 320 224 < 7 
For state approval in i~u~ology laboratories are required to obtain at least 
75% agree~cnt ~ith referee laboratories. In this set of speci~ens the referee 
laboratories (Lab. ~;os. 70, 71, and 72) received an average score of 72.37.. There-
fore, the ~ini~~ acceptable score for state approval on this shipment is 7S~ of 
72.37. or 54.2X. }~l laboratories except one received acceptable scores due to the 
repeated poor perfor~nce of the referee l~boratories. Of the 53 test reports 
returned, 3S received scores of 100:~, 7 received scores of 83'%, 10 received scores 
of 67% and 1 received a score of 337.. 
This ship~ent of speciccns ~as a repe~t of the first shipment with chan;ed 
sequence and nu~~erins. Specirr.en n~~bers SB-1-74, 5B-2-74, 5B-7-74 anc SB-9-74 
are all the sau:c pools. Specimen numbers 58-3-74. 53-4-74, SB-8-74 and 53-10-74 
are all the sa~ pools and sp~cir.0n n~~bers ~E-5-74. SB-6-74, SE-11-74 and S~-l2-74 
are all the same pools. Lnboratnrics ~hould co~pare their re~ults on these three 
pools to obtain an estim3te of within laboratory rcproJucibility. 




1. 1-1. Kit (}!icro. Sci.) 
Monospot (Ortho) 



























Some laboratories consistently do well while others consistently do poorly 
witb the S211:e tests. We are ette:-:pting to deternine reasons for these differences 
and hope that the results will help laboratories iT:lprove their perfort:' .. ~mce. 
Your pnrtic1p:.!.tion in this pro~ra.m is apprectated. If there are any questions 
concerning the program or your results please contact us. 
Sincerely, 




In~runolorv Proflcirncv !entine and Infectious Yononuc1c('\s!s Test F.vn1untlrn ~rsults 
Samele r;os. SB-7-74 SB-8-74 SP.-9-74 51\-10-74 SB-1l-74 ~R-l:?-74 
Lab. Nos. ~~:!'(! 
1.3 neg pos neg pas pas pos 1 :-0 .. 
2.3 neg w. pas neg w. pos pas pos 1:') 
3.7 neg v. pas neg v. pas pos pas 100 
4.5 neg pas neg pos pos pas EO 
5.4 neg pos neg neg pos pas !) 
6.2 ne~ neg ne~ pas pas pas !3 
6.3 neg neg neg pas pos pos n 
7.3 neg pos neg pas pos pos ICO 
8.8 neg pos neg pos pos pos l~l 
10.5 neg neg neg neg pos pos 67 
11.81 neg neg neg pas pos pos ~3 
11.82 neg neg neg pos pos pos S3 
12.6 neg neg(?) neg neg(?) pose?) pose?) 67 
12.8 neg v. pos. neg w. pos pos pas 1:'0 
13.3 neg neg neg neg pos pos 67 
14.4 neg pos neg pos pos pos 1:0 
15.3 w. pos neg v. pos ne~ pos pos .33 
16.3 neg pos neg pas pos pos ::J 
17.3 neg neg neg w. pos pos pos ~3 
19.5 neg pos neg(?) pos pos pos l':?D 
20.9 neg pas neg pos pos pas 1:0 
22.3 neg pos neg pas pos pos 1 ~0 
23.7 neg v. pos neg w. pos pos pos 1:': 
25.5 neg pos neg pos pos pos l:D 
26.7 neg neg neg neg pos pos ·67 
27.3 neg pos neg pos pos pas 1':;,0 
3,1.7 neg pos neg pas pos pos l:~ 
32.3 neg pos neg pos pos pos 1':0 
33.3 neg pos neg pas pos pos 1:0 
34.2 neg pos neg pos pas pos ICO 
34.4 neg pos neg pas pos pos l:,~ 
39.3 neg pos neg pos pos pos 1':'0 
40.1 neg pos neg pos pos pos 1:0 
43.4 neg pos neg pos pos pos 1:0 
44.8 neg neg neg neg pos pos 1::7 
46.5 neg pos neg pos pos pos E:l 
51.5 neg pos neg w. pos pos pos 1::> 
52.5 neg w. pos neg w. pos pos pos l~O 
52.8 neg v. pos neg w. pas pos pos 1':.0 
53.3 neg pos neg pos pos pos i:;o 
54.5 neg pos neg pos pos pos 100 
.55.3 neg pos neg pos pos pos ;:~ 
56.32 neg neg neg neg pos pos ~7 
58.8 neg v. pos neg w. pos pos pos l'~O 
.. 1 -
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TABU: ! (,~ont'd) 
Samf!le Nos. SS-7-74 fiR-S-74 SB-9-74 513-10-74 SB-1l-74 S!,\-12-74 
Lab. Nos. ~ 
59.5 neg w. pos neg w. pos pes pos 100 -
61.3 neg pos neg pos pes pes leO 
62.3 neg w. pes neg w. pes pes pes 100 
63.8 neg w. pes neg w. pos pos pes 100 
64.4 neg neg neg neg pos pes 67 
65.3 neg neg Deg neg pos pos 67 
70.6 neg neg neg neg pos pos 67 
71.6 neg neg neg neg pos pos (,7 
72.2 neg pos neg neg pos pos 83 
-9Q.7 
Your laboratory code number is __ _ 
- 2 -
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l-1EMORANDUH 
TO: Participants, 1~~uno]ogy Proficiency Testing Program and Infectious 
l-~nonucleosis Te~t Evaluation Program 
FROM: Bureau of I.aboratories, Laboratory Improvement Program 
SUBJECT: 1. 1-1. Test Results - Shipnent No.3, 1974 
On 6 Hay 1974 six infectious mononucleosis test evaluation and proficiency 
testing speci~ens ~ere shipped to participating laboratories. Table I shows the 
results obtained by each laboratory and their score. 
The target values for these sa~ples were as follows: 
navidsohn Differential 
SEecil1'en No. Slide Tests Unabs. G.P.X. Abs. B.E. 
SB-13-74 E.nd 
SB-15-74 Neg < 10 < 7 < 7 < 7 
SB-14-74 and 
SB-18-74 Neg < 10 56 56 56 
SB-16-74 and )-SB-17-74 Pos 160 112 • 14 < 7 
Abs. 
For state approval in ir:~unology, laboratories are required to obtain at least 
75% agreement ~ith referee laboratories. In this set of speci~ens the referee labora-
tories (Lab. :~os. 71 and 72) received an average grade of 1007.. Therefore, the 
minl~um acceptable grade for state approval on this shipcent is 751.. Seven of the 
49 participating la~oratories received the unacceptable score of 67~. Three labora-
tories received scores of 83:, with the re~inder receiving scores of 100%. 
Tabulation of errors by type of test used gave the following: 
TEST % OF TESTS % OF ERRORS RATIO ~:r./:':T 
--J 
Davidsohn 5.9% 0.0% 0.0 
1'lono Test 33.3% 18.8% 0.6 
tlollospot 17.6% 25.0% 1.4 
ttouosticon 13.7% 43.8% 3.2 
Ox-Cell Hemolysin 3.9% 0.0% 0.0 
Digluto 7.8% 0.0% 0.0 
I. M. Kit 13.7% 0.0% 0.0 
Dri-Dot 2.0% 12.5% 6.3 
Bacto-Heterol 2.0% 0.0% 0.0 
The ratio of percent error to percent of tests is an indication of how well 
the test performed on thi~ set of specimens. Little wei!,ht should be given to 
the Dri-Dot results since this represents results on only one laboratory. X2 
analysis revealed that the results 'Were highly significant with p « .001. 
FC!urteen of the 16 errors on this shipr.:ent were on speciclens 14 and lB. 
145 
These speci~ens were desi£ncd to give false re~ults if no absorption or incohplete 
absorption procedures were used. Since the lIDnosticon test can be done either 
with or without absorption, some of the errors reported vith this test t1'.ay have 





Ittmuno1oGI Proficiencv T~stin~ and Infectious ~:ononucl (>05 is TC5t Evaluation Rc~ultR 
SamE,Ie Nos. SB-13-74 SB-14-74 Sil-1S-74 S13-16-74 sn-17-74 ~B-18-7t. 
Lab. Nos. ~~ 
01. neg neg neg pas pas neg ICC:: 
02. neg neg neg pos pas neg lOC~; 
03. neg neg neg pos pas neg 10C', 
04. neg pas neg pos pas pos 6-~ I. 
05. neg neg neg pas pas neg 100:: 
06.3 neg neg neg pas pos neg I(,O~. 
06.2 neg neg neg pas pas neg lOI)~: 
07. neg pas neg pas pas pos 6 ... · I .• 
08. n.eg neg neg pas pas neg lO(l~~ 
09. neg ncg neg pas pos neg lOC', 
10. neg pos neg pos pas neg S3~: 
11. neg neg neg pas pas neg 100::; 
12.4 neg neg neg pas pas neg 100:; 
12.6 neg neg neg w. pos w. pos neg lCO% 
13. w. pos neg neg pas pas neg 83~ 
14. neg neg neg pas pas neg 1Or::"; 
15. neg neg neg pos pas neg ICC. 
16. neg neg neg pas pas neg 10 c.:; 
17. neg neg neg pas pas neg 10C\ 
19. neg pas neg pas pas pas 67;: 
20. neg pas neg pos pas pas 6i;'; 
21. neg neg neg pos pas neg . ICC:; 
22. neg neg neg pos pas neg H)C.~; 
23. neg neg neg pas pas neg lOu:; 
25. neg pas neg pas pos pas 6i~ 
26. neg neg neg pas pas neg 1O~:. 
27. neg neg neg pos pos neg 10::';:' 
31. neg neg neg pos pas neg 1C::'~; 
32. neg neg neg pas pas neg lOY; 
33. neg neg neg pas pos nes lOCo. 
34~2 neg ncg neg pos pos neg lC:~: 
34.3 neg neg neg pas pas neg ICC:. 
36. neg neg neg pas pas neg lC:~. 
39. neg neg neg pas pas neg lO~\': 
40. neg neg neg pas pos neg lOC:o 
43. neg neg neg pas pas neg 10:-:: 
44. neg ne& neg pas pas neg lr~,' 
46. neg pas neg pas pos neg 67~ 
51. neg w. pos neg pos pos w. pas 6~-I .• 
52.41 neg neg neg pas pas neg 10:"; 
52.82 neg neg neg pas w. pas neg l('~~; 
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TARLE I (cont'd) 
Immunologv l'rofidtncv Testin~ and Infectious Hononuc1C'osis Test Evaluation Results 
Sa!!!E1e Uos. SB-13-74 SB-14-74 SR-IS-74 SB-16-74 SB-17-74 SB-IS-74 
Lab. Nos. §..~ 
53. neg neg neg pas pos ne's lr~:; 
54. neg neg neg pos pos neg Ie" 
55. neg neg neg pos pos neg Ie: ~~ 
58. neg neg neg pos pas neg lC~: 
61. neg neg neg pos pos neg lC:~; 
62. neg neg neg pos pas neg 10::. 
63. neg neg neg pos pos neg lC=;~ 
64. neg neg 7 pos pos neg f~" 
11. neg neg neg pos pas neg 10:~; 
72. neg neg neg pos pos neg 
i -= 94.5:" 
Your laboratory code n~er is ______ __ 
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August 1, 1974 
TO: Participants, I~~~ology Proficiency Testing Program and Infectious 
)Iononucleosis Test Evaluation Program 
FROM: Bureau of Laboratories, Laboratory Improvement Program 
SUBJr:CT: 1. l'!. Test Results - Shipment No.4, 1974 
On 8 July 1974 six infectious mononucleosis test evaluation and proficiency 
testing specim~ns were shipped to particip.:lting laboratories. Table 1 shol,'s the 
results obtained by each laboratory and their score. 
The target values for these sacples ~ere as follows: 
Ox-Cell Hemolysin Davidsohn Differential 
Specil!'en No. Slide Tests (CDC J.lethod) Unabs. G.P.K. pbs. B.E. 
SB-20-74 and 
SB-2l-14 neg < 10 < , < 7 < 7 
S8-19-74 and 
.SB-24-74 neg < 10 S6 S6 S6 
SB-22-74 and 
SB-23-74 pos 160 112 ~ 14 < 7 
Abs. 
For state approval 1n i~~unology, laboratories are required to obtain at least 
75% agrec~ent with referee laboratories. In this set of specirr~ns the referee 1abc~a­
tories (Lab. Nos. 71 and 72) received an averaee grade of lOOZ. Therefore. the 
mininurw acceptable grade fot state approval en this ship~ent is 75%. Four of the 
S2 participating laboratories received the unaccept?ble score of 67% and one received 
a score of 50%. Two laboratories received scores of 83%, with'the remainder re-
ceiving scores of 100%. 
We are in the process of analyzing the sensitivity, specificity and re;producibi1i::: 
of the various tests in \lse \.'ithin the state and hope to be able to report these 
results to participating laboratories in the ncar future. t..'e are also an:\lyzing 
factors ",hich m.w i'lffect tC!;t performance ;n1l.1 "-"ill include these results in the 
report. 
Your cooperation in this project has been appreciated. 
Sincerely, 





Imrnunolor..v Proficiency Testin(>. and Infectious l!ononucleosis Test Evaluat1~n Pesu!tn 
Sa!1lflle Nos. SB-19-74 SB-20-74 SB-21-74 SB-22-74 S1'l-23-74 SB-?4-74 
Lab. Nos. Score 
01 neg neg neg pos pos neg 100;; 
02 neg neg neg pos pos neg 100 
03 neg neg neg pos pos neg 100 
04 pos neg neg pos pos neg 83 
05 neg neg neg w. pos pos neg 100 
06.2 neg neg neg pos pbS neg 100 
06.3 neg neg neg pos pos neg 100 
07 neg neg neg pos pos neg 100 
08 neg neg neg pos pos neg 100 
09 neg neg neg pos pos neg 100 
10 neg neg neg pos pos neg 100 
11 neg neg neg pos pos ncr, 100 
12.6 w. pos neg neg pos pos v. pos 67 
12.8 v. pos neg neg pos pos, v. pos 67 
13 neg neg neg pos pos tleg 100 
14 neg neg neg pos pos neg 100 
15 neg neg neg pos pos r.eg 100 
16 neg neg neg pos pos neg 100 
17 neg neg neg pos pos neg 100 
19 neg neg neg pos pos neg 100 
20 neg neg neg pos pos neg 100 
21 neg neg neg pos pos neg 100 
22 neg neg neg pos pos neg 100 
23 neg neg neg pos pos neg 100 
25 neg neg neg pos pos neg 100 
26 neg neg neb pos pos neg 100 
27 neg pos pos pos pos pos 50 
31 neg neg neg pos pos neg 100 
32 neg neg neg pos pos neg 100 
33 neg neg neg pos pos neg 100 
34.2 neg neg neg pos pos neg 100 
34.8 neg neg neg pos pos neg 100 
36 neg neg neg w. pos pos neg laO 
39 neg neg neg pos pos neg 100 
40 neg neg neg pos pos neg 100 
43 neg neg neg pos pos neg 100 
44 neg neg neg pos pos neg 100 
46 neg neg neg pos pos neg 100 
51 pos neg neg pos pos pos 67 
52.4 neg neg neg pos pos neg 100 
52.9 neg neg neg pos pos neg 100 
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TABLE I (cont'd) 
Immunolof.Y Proficicncv Tcstlnc and lnfl'ctjou!: }!ol1C'nl!clcos'is Tc~t Evnluation Rc~ults 
Samele Nos. 513-19-74 SB-20-74 SB-21-74 SB-22-74 S'B-23-74 5B-24-74 
I,ab. Nos. ~ 
53 neg neg neg pos pos neg lOC~ 
54 neg neg neg pos pos neg 100 
55 neg neg neg pos pos neg 100 
56 neg neg neg pos pos neg 100 
58 neg neg neg neg pos neg B3 
59 w. pas neg neg pos pas w. pos 67 
61 neg neg neg pow pos neg 100 
62 neg neg neg pas pas neg 100 
63 neg neg neg w. pos w. pos neg 10C 
64 neg neg neg pos pos neg 100 
65 neg neg neg pos pos neg 100 
71 neg neg neg pos pos neg 100 
72 neg neg neg pOB pos neg 
-1.Q2... 
i 96.0 
Your laboratory code no. is ___ _ 
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TO: 
FROM: 
BUREAU 0 .. LABORATt'i<!1 ..• 
Participants. Immunology Proficiency Testing Program and Infectious 
Mononucleosis Test Evaluation Survey 
Bureau of Laboratories, Laboratory Improvement Program 
SUBJECT:' I. M. Test Evaluation Report 
During the year the Utah State Division of Realth has been c~nducting 
an evaluation of tests for infectious mononucleosis 1n conjunction with 
its immunology proficiency testing program. This report cont.ins a brief 
s~~ry of the findings obtained by ~eans of this evaluation. If there are 
any questions or if more information is desired please contact the Bureau 
of Laboratories, Laboratory Improvement Program. 
Table I shows the evaluation of results b~ type of test indicatin~ the 
sensitivity. specificity, reproducibility a~d agreement achieved by each 
test. 
Monotest ('(.;enpole) "as by far the most frequently used test in this 
evaluation (27/88 cr 30.7%) .nth !-!onospot (Or tho) (13/88 or 14.8%). XClnosticon 
(Organon) (10/86 or 11.4%). I. M. Kit (}licro. Resh. Corp.) (10/88 or 11.4%), 
Diagluto I. M. (Beck~) (S/B8 or 9.1:) and Monosticon Dri-Dot (Organon) 
(7/88 or 8.07.) following. 
Of the tests USE'd uy three or Iolore lahorator;1es the nost sensitive was 
MonostiC{lt'l Dri-Dot (Organon) (lOO~n sr,d the It:8st sensitive was the ox-cell 
hemolysin (68.8~:). The Davidsohn differential and Diaf!luto I.!-I. (Beckcan) 
both achieved 1007. specificity with }!o:losticon (Organon) and !'10nositcon 
Dri-Dot (Orgallon) receiving the lc",.est specificity (87.0% and 86.6% respectively). 
There was an inversely proportior.al relationship between sensitivity and spec-
ificity (P < .02), i.e., as secsitivity increased specificity decreased. 
Within shipI:".ent reproduci~il1ty was consistant1y about 5 percentage points 
higher than the between shipment reproducibility (P « .001). 
The Davidsohn differential obtained the best agreement with target values 
but it ~as not ~ignificantly better than the slide tests. None of the dif!er~nces 
in tests were si~nificant. 
Although there were a number of changes in test use, frequtntly mUltiple 
changes, eighty percent of the laboratories did not change tests during the 
evaluation. 
Performance improved during the evaluation as reveoaled by the fact that 
agreement was 5 percentage points higher for the ~econd half than it was . 
for the first half (P < .05). Presumably this was attributable to increased 
proficiency which resulted from the educatipnal and corrective influence of 
proficiency testing. 
Private hospitals achieved significantly lower sensitivity (P < .01) and 
agreement (P < .05) than other types of laboratory. Sensitivity was 69.0% 
versus 93.3% and the agreement was 82.2% versus 92.8% respectively. Thus, 
private hospitals are more likely to miss a case of infectious mononucleosis. 
technologists with a baccalaureate degree achieved a little better 
agreement (92.87.) than did either the high school graduates (90.0~) or the 
technologists ~~th r~sters degrees (89.87.) but the differences were not 
statistically significant. The one "technologist" with a doctorate did 
very well (100% agree~ent, specificity and sensitivity) but his perfor~~nce 
was not significantly better than any other group. 
The two I.S.C.L.T. registered technologists were about 10 percentage 
points lower in agreement (79.5% vs. 92.8%) than the other groups (A.S.C.P., 
A.M.T. and non-registered technologists). Sensitivity was also lower for this 
group (66.5% vs. 92.1%). 
Experience of. the technologist made little difference, but in general 
the group with 3 to 10 years of experience 'performed the best, followed by 
the.group with 0 to 2 years, and the group with more than 10 years experience 
did the poorest. Experience with the particular test being used had about 
the same results. Technologists with 3 or more years of experience with the 
particular test had signif::l.cantly 1010ler (P < .05) sensitivity (85.2% vs. 93.81.) 
than the other groups. Apparently, experience increases performance up to 
a point after which performance deteriorates to a level lower than those with 
no e:xperlence. 
MOst laboratories (54.5%) used a procedure which did not involve any 
absorption, and most of the laboratories (757.) which used an absorption 
procedure used both guinea pig kidney and beef eryth1:ocytes. There were 
no significant differences among the ~arious absorption procedures. 
There were no significant differences a~ong the different agglutination 
end points and the significant differences in the 50 hemolytic end point was 
probably not due to the test itself. 
Both the length of time the speci~ens were held before testing and the 
temperature at which they were held had an effect on the reliability of the 
test. Specificity, reproducibility, and agreement were all lower for specimens 
held over one week before testing than they were for those tested within one 
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week. Sensitivity. t'l1)ecificity and IIp,reer.ient were all lower for spec1~ens 
held at room temperature than they WE're for specimens held at refri~erator 
temperatures, but reproducibility ,,:as higher "'hen speci:::lens were held at room 
te~perature. ~~en the combined effects of ti~e and temperAture were evul-
uated it wasobserved that all of the parar'eters ..... ere.2 to £; percentage points 
lower for the specimens which were held the longest times and the highest 
temperatures. 
We were unabie to evaluate the effect of controls since 96% of the labora-
tories used at least a positive control. 
Most laboratories (52.4%) used ~he s~me test as both screen and con-
firmation and many laboratories (41.5%) used the tests only as screens. There 
were no significant differences in tests by use. 
Most l;Jboratories (79.8%) used tests in Vhich the technologists had ugood" 
confidence and none of the laboratories used tests in which the technologists 
had "poor" confidence. Although none of the differences were significant the 
tests in which. technologists had only "fair" confidence perfotred slightly 
better in general than did the tests in ""hich tha technologist expressed "good" 
confidence. 
In general, technologists specializing i; hematology or blood banking 
obtained the best results, with bacteriologists and serologists next, and 
chemists and general medical technologists obtained the poorest results. 
Beef cells obtained significantly lower (P < .05) agreement (79.2~ VS. 93.l%) 
than fresh sheep cells or the three groups of-horse cells. The beef cells were 
also less sensitive (P < .01) than the other cells (68.8% vs. 92.6%), but this 
was probably due to evaluation problel~ rather than inadequacy of the cells 
or the test. 
As the nu~ber of serologic tests perfor~ed annually in the laboratory 
increased the performance increased although some of the differences were 
not significant. Similar results. were observed with the nu6her of tests for 
infectious ~ononucleosis perfor~ed in the laboratory. but there was a point 
after which perf6rr~nce declined. 
One-man laboratories achieved significantly higher (P < .OS) total re-
producibility (98.0% vs. 93.3%) than other laboratories. Agreepent increased 
as the number of tecbnicians increased. with the laQoratory vith more tr.an 
five technicians achieving significantly better (P < .05) agreement (95.5% 
VS. 91.7%) than laboratories with only one technician. 
Table II whows the reported costs by type of test. There were no signi-
ficant differences between the reported cost and ti~e requirements for the 
two standard test, nor among the slide tests. The standard tests required 
30.0 ± 7.1 r~nutes to perform and cost $2.48 ± .14 for cost of ~~terials 
and technologist's ti~e. The slide tests required 6.5 ± 2.6 minutes to per-
form and cost $1.46 ± .44 for ~ateria1s and technologist's time. 
-3-
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Subjective evaluation of the tests shOl.·ed that speed and ease of per-
fonnance ""ure the t:lost frequently IllCntioned advantages and cost and lack 
or" titer were the t:lost frequently t:lentioned disadvantages. 
It scens that a sr.;nll la!loratory could do satisfactory testing for 
infectious mononucleosis by selecting one of the slide tests that meet their 
require~~ats for cost, shelf life, titer capahility, etc., and using it properly. 
For larger laboratories the slide tests would serve well as screens with the 
standard tests (Davidsohn differential or ox-cell hemolysin) used for titration 
when they are requested or for confi~~tion. 
Even though most of the parameters measured and variables evaluated 
exhibited substantial differc~ces they ~ere usually not significantly different 
due to the small sa~ple size in some cases and large variation in most cases. 
This points out the need for si~~lar evaluations using larger proficiency 
testing programs. Similar programs should also be conducted to evaluate other 
types of tests so that test selection can be tr~de on the basis of measured 
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TABLE I 
Evaluation of Results by Type of Test 
% ", 't.i \ 't.i \'t.'''' \~\" Reproducibi 1 i ty 
Test No.* of (\s e" 
total se S~ Within Between Total Agreerr:er.: 
Bacto-Hetrol (Difco) . 2 2.3 100.0 100.0 100.0 100.0 100.0 100.0 
Dav; dsohn 
Differential 4 4.6 91.8 100.0 96.0 92.0 96.0 96.0 
Honotest 
(Wampole) 27 30.7 90·7 96.3 99.0 89·4 94.6 93.0 
Honospot 
9"1.2 (Ortho) 13 14.8 95.S 94.2 97.5 95.6 94.3 
Honosticon 
(Organoni 10 11.4 92.6 87.0 96.3 91.4 95·9 88.3 
Ox.Cell 
Hemolysin 4 4.6 68.8 95.8 100.0 83.S 89.0 79·2 
Dlagluto 
84.4 (Beckman) 8 9·1 100.0 97.9 94.3 96.5 90.6 
I.H. Ki t 
(MicroResCorp) 10 11.4 91.7 96.7 95.1 91.6 93·9 92.2 
Od-Dot (Organon) 7 B.O 100.0 86.6 96.0 89 .. 5 94.7 93.3 
Mono.Diff 
(Wampole) 1. 1 100.0 100.0 100.0 100.0 100.0 
Honophile 
(Bio.Diagnostic 
Systems) 1. I 100.0 100.0 100.0 100.0 100.0 
Rythrotex (BMC) 1 1 • 1 100.0 100.0 100.0 100.0 100.0 
Total 88 100.0 92.4 94.8 97·6 90.4 95.1 92.4 
* indicates nu~ber of laboratory-technologist co~binations (some 
laboratories had n~re than one technologist r~portin9 or more than 




Reported Costs by Type of Test 
Time Materi at Total No. of 
Test Time (mi n) cost ($) cos t ($) cos t ($) reports 
Bacto-Hetrol 
(Oifco) 12.5 :!:. 2.9 LOB:!:. .38 .60 :!:. .49 1.68 !. .36 5 
Oavidsohn 
Oi fferent i a 1- 35.0 :t 8.7 2.12 + .12 .46 :t .05 2.58:t .11 3 
Monotest 
(Wampol e) 7.0 :t 5.8 0.60 :t .49 .47 :t .24 1.07 :!:. .53 24 
Monospot 
(Ortho) 6.7 :t 2.5 0.43:!:. .1] 1.36:t .81 1.70 :!:. .60 9 
Monosticon 
(Organon) 6.6 :!:. 3.1 0.46 + .20 1.48 :!:. 1. 11. 1.94!..82 10 
Ox-Cell 
Hemolysin 25.0 :t 17 .-3 1.75 + .43 .63 :!:. .29 2.38 :!:. .72 3 
Oiagluto 
(Beckman) 7.8 :t 4.7 0.49 :t .31 .70 :!:. .56 1.38 ::.!:. .45 5 
r.M. Kit 
(M,icroRshCorp) 5.2 !. 2.1 0.58 :!:. .39 ~ 6J + .28 1.19 !. .58 9 
Dd .Dot 
(Organon) 6.4 :!:. 3.4 0.61 ::.!:. .32 .99 !. .40 1.60 + .40 7 
Mono.Oiff 
(Wall1P.oJ e) 5.0 :!:. 0 o. 25 ~ 0 2.00 + 0 2.25 :!:. 0 
Monophile 
2:0 +' 0 ( B i 0 - 0; a 9 -S Y s) 0.14 + 0 ) .00 + 0 1.14+0 
Rythrotex 
( 611C) 6.0 + 0 0.42 + 0 .37 :!:. 0 .79 !. 0 
x + SO 10.4 !. 9.7 0.74 !. .6J .89 !. ·50 1.61 !. .55 78 
lube test 
total 30.0 :!:. 7. 1 1.94 !. .26 .54 :!:. .12 2.48 + .14 2 
SI.de test 
total 6.5 !. 2.6 .51 !. .25 .96 !. .52 1.46 + .44 10 
Total 10.4:!:.9.7 0.74 !. .61 .89 :!:. .50 1. 61 !. .55 12 
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